Category: ACN Newswire

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 領先的機電工程與智慧城市的資訊及通訊科技服務供應商安樂工程集團有限公司（「安樂工程」或「公司」，連同附屬公司統稱「集團」）（股份代號：1977），今天宣佈截至2025年12月31日止年度（「年內」或「2025財政年度」）的全年業績，除淨利潤錄得增長，集團的手頭合約更再創新高，訂單額增長逾倍，為未來三年及往後的發展奠下穩固基礎。財務摘要- 本公司擁有人應佔溢利按年增23.5%至1.670億港元- 手頭合約增61.8%至178.787億港元，再創歷史新高，受惠於年内訂單額增長113.7%至129.136億港元- 新增維修保養合約涵蓋房屋項目、環保項目以及升降機及自動梯，合約額增51.4%至16.69億港元，鞏固經常性收入來源- 集團維持強健現金水平，銀行結餘及現金為10.208億港元，資產負債比率則由26.2%降低至2025財政年度的10.1%- 董事會已決議派付第二次中期股息每股2.9港仙；全年合共派息每股5.5港仙，較上年度増25.6%主席麥建華博士表示：「2025年見證了全球的重大變化，挑戰與機遇並存。集團穩步向前，以謹慎履行承諾作堅實基礎，不斷精益求精，更推動革新落到實處、投資提升技術及生產力，引領香港工程的卓越實力踏上環球市場。我們欣然宣布，集團實現了利潤增長，更創下歷史新高的手頭合約水平，並持續鞏固在國際市場的影響力。這些成就彰顯了我們在各個業務領域的綜合能力，對卓越品質的承諾，以及在先進工程技術方面的領導地位。」「憑著充裕的現金流支持，我們具實力適時開展更多工程項目，並在高價值商機出現時抓緊機會。我們將繼續保持靈活專注，積極把握集團廣泛業務組合中的機遇，透過持續提升我們具競爭力的優勢，並強化應用創新解決方案，以提升工程品質、安全和表現。我們深知為客戶堅定不移地履行承諾，是贏得他們信任及維繫持久夥伴關係的基礎。秉持『重承諾、慎履行、獻成果』的座右銘，我們將繼續為客戶、股東、供應商和其他持份者創造最高利益，同時為我們所服務的社區作出貢獻。」業務回顧：屋宇裝備工程- 此業務板塊繼續成為集團最大的收益來源，收益達32.79億港元。- 手頭合約創下歷史新高，達82.97億港元，於2025財政年度新簽合約增長一倍達64.70億港元。集團在跨多專業的綜合項目中擁有競爭優勢，並有賴在創新的機電裝備合成法和其他新工程技術方面的領導地位成功取得重要合約。- 憑藉策略性投資以加快創新，並在珠海和香港發展現代化製造設施，集團得以在機電裝備合成法和裝配式設計技術方面繼續領先同儕。- 集團通過成功取得物業管理牌照擴大業務以提供可橫跨整個建築週期的綜合解決方案。此涵蓋建造、維修保養、營運，以至長期的設施管理的新能力，開拓了潛在的收益來源，與核心服務互補優勢。- 透過不斷開發創新技術和優化營運，此業務板塊強化自身定位以維持在市場中的競爭優勢，同時探索東南亞其他市場的發展機遇。環境工程- 此業務板塊的手頭合約與新增訂單額創下歷史新高，分別按年增加86.9%及253.7%至80.94億港元及53.55億港元。同時，業務收益按年增加18.0%至15.91億港元。- 此業務板塊於年內維持積極參與投標，並成功贏得標誌性合約，包括合約額破紀錄的搬遷沙田污水處理廠往岩洞、馬鞍山污水泵房等工程項目。- 於慶陽市開立了合營企業，以拓展中國內地的營運及維修業務。- 探索在亞洲和中東地區的項目機遇，並將專業服務拓展至歐洲市場。資訊、通訊及屋宇科技（「ICBT」）- 業務收益維持在6.30億港元，手頭合約價值截至2025年末為8.52億港元，年內新增訂單額為5.23億港元。- 此業務板塊持續以DigiFusion品牌鞏固其在綠色及智慧屋宇解決方案的領導地位，有助打造更智慧化、更可持續的城市環境。- 持續憑藉安樂工程大廈作為平台以研發創新技術，並透過與中國內地及環球領先生產商的策略合作持續擴大技術能力，從而加強在多個範疇的能力以提供可擴大規模的高效解決方案。升降機及自動梯- 收益與新增訂單額分別按年增加11.0%至5.87億港元，以及增加3.2%至5.66億港元。- 集團位於美國的聯營公司Transel Elevator & Electric Inc （「TEI」）取得重大合約，在聳立於紐約時代廣場旁的地標性56層摩天豪華酒店內提供世界級垂直運輸系統。TEI亦將業務版圖拓展至美國東南部，進一步鞏固其市場地位。- 積極加強在英國的業務，並擴大在其他國際市場的網絡，強化在垂直運輸解決方案領域的全球發展的雄心。- 無機房升降機產品繼續在主要國際市場取得進展。- 南京工廠簡化了生產流程，擴大產品種類，並提高了整體產品質量。這些提升正好配合集團的環球視野，肯定其承諾，矢志提供可靠和高效的垂直運輸解決方案。有關2025年度業績詳情，請參閱已呈交香港聯合交易所有限公司的公告。關於安樂工程集團有限公司安樂工程集團有限公司成立於1977年，為領先的機電工程與智慧城市的資訊及通訊科技服務供應商，總部設於香港，業務遍及中國內地、澳門、美國、英國、德國、新加坡及馬來西亞。本集團為公共和私營機構提供跨專業綜合機電及技術服務，涵蓋屋宇裝備工程、環境工程、資訊、通訊及屋宇科技（「ICBT」），以及升降機及自動梯等四大業務板塊。本集團同時製造及向全球銷售升降機及自動梯，並與美國紐約最大獨立升降機及自動梯公司之一 – Transel Elevator & Electric Inc.（「TEI」）達成夥伴關係。本集團的聯營公司南京佳力圖機房環境技術股份有限公司（603912.SS）專門製造精密空調設備。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月26日，海天味業（A股：603288；H股：03288）發佈2025年年度業績報告，面對2025年複雜多變的市場環境，憑藉多元產品矩陣、高效運營體系、硬核科技創新，公司在行業變革浪潮中穩健前行，交出一份彰顯行業龍頭實力與高品質發展成色的優異答卷。財報資料顯示，2025年公司核心經營指標穩健增長，實現營業收入288.73億元，同比增長 7.32%。盈利能力同步提升，全年歸母淨利潤70.38億元，同比增長10.95 %；扣非歸母淨利潤68.45億元，同比增長12.81%；調味品主業毛利率41.78%，同比增加3.15個百分點；各項經營資料均創下歷史新高，盈利品質與增長動力雙雙亮眼，彰顯公司硬核實力。豐富的國民產品矩陣，構築多元增長格局豐富完善的國民級產品矩陣，是海天味業實現穩健增長的核心基石。在產品矩陣方面，海天圍繞用戶需求持續推進品類創新，構建起覆蓋全場景烹飪的一站式產品體系，全方位滿足不同消費群體的多樣化需求。得益于豐富的產品矩陣與優異的產品品質，2025年，公司醬油、蠔油、調味醬等核心品類保持穩健發展，分別實現營業收入149.34億元、48.68億元及29.17億元，同比增長8.55%、5.48%及9.29%，構成業務增長的“金字塔基座”。其中，海天醬油產銷量和市場佔有率已連續數十年位居全國第一，海天蠔油的市場佔有率也連續10年位居全國第一，憑藉優質口感與穩定品質，成為千萬家庭與餐飲機構的首選；公司調味醬已形成產品豐富、風味立體、場景多元的產品體系，涵蓋黃豆醬、香辣醬等具備廣泛消費基礎的大單品，同時亦有柱侯醬、海鮮醬、拌飯醬、香菇醬等適用不同烹飪方式的特色醬料，紫蘇醬、桂林風味辣椒醬等適合不同地域口味的風味醬料，以及蔥油拌麵醬、重慶小面調料等便捷化調味醬，有效滿足用戶需求。此外，為順應消費者對醋類產品的細分化需求，公司堅持「傳統醋+特色醋」的產品佈局，同時不斷推陳出新，推出有機醋、果醋等多元化產品，形成豐富多元的醋類產品體系，進一步彌補品類空白，擴大市場覆蓋面。截至2025年底，公司擁有7個十億級以上產品系列、超30個億級以上產品系列，產品矩陣的豐富度與完整性持續提升。其中，金標生抽、草菇老抽兩大產品系列已暢銷60餘年，味極鮮醬油、海天上等蠔油兩大產品系列連續10餘年實現單品年收入超10億元，成為支撐公司業績穩健增長的「壓艙石」，其市場認可度與用戶忠誠度持續處於行業領先水準。在保持核心品類穩健增長的同時，海天精准把握消費趨勢變化，持續培育新興增長點，不斷豐富產品矩陣的層次與內涵。報告期內，在領先行業的產品力支撐下，以有機和薄鹽為代表的營養健康系列產品實現營業收入同比增速達48.3%，成為拉動業績增長的新引擎；食醋和料酒業務持續發力，規模優勢和體系化能力逐步顯現，市場佔有率穩步提升，為公司長遠發展注入強勁新動能。值得關注的是，依託供應鏈規模效應、技術研發與柔性生產三大核心壁壘，海天加速從“調味產品供應商”向“一站式風味解決方案提供商”轉型，深度佈局商用市場，實現To C與To B業務雙輪驅動。截至2025年底，公司已為眾多餐飲連鎖、食品工廠及全球頭部零售品牌提供商用調味品一站式解決方案，成為公司業績增長的重要支撐。堅持以用戶為中心，全域深耕驅動效率與價值雙升堅持以用戶為中心，持續優化運營效率與用戶價值，是海天味業保持行業領先地位的關鍵所在。面對消費渠道的多元化變革，海天立足用戶需求，通過數字化賦能傳統渠道、擁抱新興渠道建設、聯動餐飲及工業渠道，實現效率與價值的雙重躍升，進一步鞏固市場滲透率。在傳統渠道方面，海天依託覆蓋全國的終端網路，借助數字化行銷工具和服務模式創新，持續向下沉市場滲透，並延伸到最終用家和消費者，顯著提高了終端覆蓋品質與消費者觸達效率，同時，通過終端管理的精細化升級，讓存量網點煥發新活力。2025年線下渠道營業收入達257.60億元，同比增長7.85%。線上與即時零售等新興陣地，海天主動適應消費場景的變化，通過規範銷售秩序、強化專業運營，實現新興渠道的高品質發展；針對新興渠道的消費特性，公司還推出線上定制化產品，精准匹配消費群體的需求，逐步構建線上與線下協同互促的健康發展模式，2025年線上渠道增幅高達31.87%。在商用渠道方面，依託柔性供應鏈與「銷研產一體化」快速回應機制，海天為餐飲連鎖和食品工廠提供從通用產品到定制化的一站式調味解決方案，實現「3天打樣、15天交付」的高效回應，大幅提升了客戶體驗與合作粘性。目前，餐飲與工業渠道穩健發展，收入占比持續提升，正成長為公司專業增長的重要動力源，進一步拓寬了公司的增長空間。堅持科技立企與創新，驅動價值鏈全面升級堅持科技立企、創新驅動，是海天味業實現高品質發展的核心動力。作為調味品行業數字化轉型的先行者，公司全面擁抱AI時代，推動人工智能、大數據與傳統釀造技藝深度融合，在守護匠心工藝的同時實現提質增效，推動行業從「傳統釀造」向「智慧釀造」轉型升級。海天味業堅持每年將研發投入保持在營業收入約3%的水準，近十年研發投入累計超65億元，累計擁有各類專利超1,000項，形成了完善的研發體系與創新機制。2025年1月，海天高明生產基地獲得全球醬油釀造行業首家「燈塔工廠」認證，標誌著公司數字化轉型已躋身全球行業標杆，也印證了中國調味品企業在智慧製造領域的領先實力。此外，公司部署端到端供應鏈創新用例，將AI與大數據深度應用於研、產、供、銷各環節，實現全鏈條的數字化、智慧化升級。在數字化全面賦能下，海天供應鏈運營效率顯著提升，訂單準時足額交付率（OTIF）不斷提高，綜合成本穩步下降，充分彰顯智慧製造帶來的效率紅利與競爭優勢。受益於在數字化轉型與高品質發展方面的突出成就，海天味業屢獲殊榮。2025年，公司斬獲「CGF中國供應鏈數字化與可持續韌性發展案例」「全國製造業數字化轉型典型案例」等多項殊榮，得到行業與社會的廣泛認可。同時，由海天主導起草的國家標準《食品數字化工廠通用技術要求》正式發佈，填補了國內食品行業數字化工廠通用技術標準的空白，為食品行業數智化升級提供「海天範式」，充分彰顯了公司的行業帶動力與責任擔當。回望2025年，海天味業以穩健業績、多元佈局、硬核實力，在高品質發展之路上行穩致遠，進一步鞏固了行業龍頭地位。展望未來，公司將繼續堅守匠心、深耕主業，持續優化產品矩陣、深化科技賦能、拓展全球市場，以更優質的產品、更高效的服務、更強勁的創新力，守護中國味道、引領行業升級，書寫中國調味品企業全球化高品質發展的嶄新篇章。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月27日，美麗田園醫療健康（02373.HK）正式發佈2025年度業績報告。年內，集團營收、利潤、現金流全方位高質量增長，以硬核業績凸顯行業龍頭的強增長韌性。集團盈利能力實現跨越式躍升。2025年，美麗田園集團總收入30億元，同比增長16.7%；毛利率提升至49.1%，同比提高2.8個百分點；經調淨利潤攀升至3.8億元，同比大幅增長41.0%，經調整淨利率達12.7%，提高2.2個百分點，盈利水平邁上新台階。公司持續顯現「現金牛屬性」。2025年集團經營活動產生的現金流量淨額達10.0億元，同比大幅增長25.4%；截至2025年12月31日，集團現金及類現金項目金額合計高達25.9億元，同比淨增41.6%，充沛且強勁的現金流為集團戰略投資與股東回報提供充足動能。這份營收與利潤大幅增長的亮眼業績，是集團「內生增長+外延並購」商業模式的成功體現，也是集團精益管理、提質增效及數智化賦能帶動整體效率提升的有力印證。「雙美+雙保健」模式賦能，盈利能力全面上揚作為核心基石業務，集團美與健康板塊逆勢高增，全年交出令市場矚目的亮眼答卷。2025年，美容和保健服務收入16.6億元，同比增長14.9%；毛利率提升1.2個百分點至41.9%；直營門店客流達172.4萬人次，同比增長23.2%；直營活躍會員增至14.6萬名，同比增長11.8%，直營活躍會員年均消費金額9738元，同比提升320元。直營活躍會員規模與年均消費實現雙增長。業績高質量增長的同時，集團錨定長期發展戰略。2025年，我們正式發佈超級供應鏈戰略，全面升級產品創研體系。未來，產品創研方式將全新拓展為全球精選、國際品牌合作、國際頂尖實驗室聯合研發三大模式並進，在傳承卓越品質的同時，注入創新動能。2026年2月，我們重磅宣佈與全球知名護膚品牌資生堂達成重磅戰略合作，在品牌影響力、服務體驗、科研共創等多維度深度攜手，開啟美與健康領域合作的新篇章。消費醫療兼具醫療價值屬性與消費彈性，是承載長期結構性機遇的優質賽道。美麗田園集團深耕消費醫療賽道，圍繞高端女性美與健康的核心醫療需求深度延伸佈局。過去16年，我們從0到1自建消費醫療能力，目前全國落地38家消費醫療機構，形成規模化佈局。2025年，消費醫療板塊整體收入13.4億，同比增長18.9%，占收入比例達到44.8%，成為重要的增長驅動力。具體來看，2025年集團醫療美容服務-秀可兒醫美逆勢增長，實現收入10.2億元，同比增長9.6%，毛利率大幅提升3.6個百分點至55.9%；客流10.2萬人次，同比增長13.1%，活躍會員攀升至3.6萬名，同比增長7.7%；活躍會員年均消費27,862元，同比增加490元。為進一步破局行業競爭、打造差異化核心優勢，秀可兒醫美精准錨定「專研抗衰」賽道，以「專家、專研、專注原生美」為品牌定位。2026年3月，Cellcare秀可兒品牌舉辦「專研抗衰」品牌升級發佈會，圍繞不同年齡層女性抗衰需求，打造 「初老抗衰、凍齡抗衰、逆齡抗衰」 的全週期產品藍圖，正式開啟秀可兒專研抗衰新時代。亞健康醫療服務--研源醫療作為集團增值業務迎來爆發式增長。2025年，研源醫療收入3.3億元，同比大增62.2%，收入佔比首次突破10%，成為集團業績增長的重要引擎；毛利率升至64.3%，同比提升6.1個百分點；客流量3.7萬人次，同比增長35.7%，活躍會員人數同比大增37.9%，活躍會員年平均消費28,032元，同比增加6287元。2025年，研源醫療旗下功能醫學板塊收入同比增長101%。在AI浪潮之下，我們將通過自研AI模型，深度融合精准檢測數據、專家診療路徑與臨床案例，實現「千人千面」的個性化診療方案與7x24全天候服務，以科技賦能醫療服務全面升級。研源醫療旗下女性特護板塊收入增長64%。我們將持續拓展服務版圖，構建「預防-治療-抗衰」女性健康醫療服務。並購整合戰略升級，以共贏之姿賦能行業發展中國「美與健康」市場坐擁萬億賽道規模，機遇與挑戰並存，合作共贏已經成為行業發展的必然趨勢。美麗田園主動投身行業整合進程，將投資並購上升為集團級核心戰略，以開放共贏的姿態攜手行業夥伴，共同推動美業高質量發展。2026年3月，集團重磅舉辦「尋找100位美業同行者」戰略投資暨行業賦能發佈會，宣佈將聚焦中國20個高線城市的美與健康服務機構，誠邀更多行業夥伴融入美麗田園生態體系，依託持續打磨精進的商業系統為行業夥伴提供全方位賦能提效，實現共生共贏。這一戰略佈局的底氣，源自集團過往逾30多起收並購項目中所積澱的深厚實戰經驗與可複製的整合方法論。2024年，集團完成對中國美容行業市占率第二大品牌奈瑞兒的收購，並通過系統化、精細化整合，實現奈瑞兒收入和利潤雙提升。2025年，奈瑞兒單店收入從收購前的575萬提升至810萬、經調淨利率從6.5%大幅提升至10.5%，以亮眼的數據印證了美麗田園強大的並購整合能力，更形成了一套可複製、可延展的行業整合成功範式。2025年10月，美麗田園集團宣佈以12.5億元人民幣全資收購行業第三大品牌思妍麗100%股權。伴隨著思妍麗於2026年1月正式併入集團報表，我們將複製奈瑞兒成功經驗，充分發揮自身模式優勢和平台能力，為業績增長注入新動能。至此，三大品牌齊聚美麗田園集團麾下，市場佔有率實現跨越式提升，中國美容行業競爭格局重塑。重磅打造商業系統，構建企業可持續增長核心壁壘33 年深耕，美麗田園集團從美容服務逐步延伸至消費醫療，已成功建成面向高線城市女性的美與健康綜合服務平台。2025年，集團重磅打造美麗田園商業系統，從多維度構建企業可持續增長模式，為長遠發展築牢體系根基。客戶價值成長系統。通過精細化客戶運營體系，我們構建起覆蓋推廣、獲客、轉化、會員留存、價值提升、複購、裂變的全鏈路運營閉環，為客戶持續創造長期價值。強平台+多品牌系統。我們構建了「強平台+多品牌事業部」協同的組織體系，支撐多品牌、多業務高效聯動與協同發展。前台事業部聚焦市場與客戶，靈活作戰、快速響應；平台沉澱能力、輸出標準，讓協同貫穿業務全流程，有效提升運營效率與業務延展性，為多品牌有序擴張提供堅實組織支撐。並購價值成長系統。我們構建了「投資+整合+成長」全週期並購價值成長體系，通過持續積累行業獨特的投資數據、成熟的投前模型、精進的投中整合，全面提升投後價值，形成成熟的並購與賦能機制，可適配不同規模、不同業務的優質標的，真正實現「並購即融合、融合即增值」。數智化與AI系統。集團將構建數智化驅動的管理體系，深度賦能美麗田園商業系統，讓體系能力可落地、可複製、可迭代，成為集團穿越經濟週期、持續引領行業發展的堅實支柱。資本市場價值提升，持續釋放長期投資價值2025年3月，集團正式發佈三大舉措，圍繞股東結構優化、高分紅比例及管理層激勵，持續向資本市場釋放長期投資價值。股東結構優化方面，2025 年 8 月，原PE股東中信產業基金正式退出主要股東行列，同步引入優質長期戰略投資者，股東結構進一步夯實。分紅方面，2026年董事會提議延續高分紅比例，將2025年歸母淨利潤的50%用於分紅，派發每股0.72港元，同比增長38.5%，以真金白銀的回報持續強化股東回報，彰顯企業對自身發展的堅定信心。管理層激勵方面，2025年，集團將未來三年收入及利潤目標與股權激勵深度綁定，首年業績目標已超額達成，激勵機制的有效性得到充分驗證。在此基礎上，公司進一步上調管理層股權激勵對應的三年業績目標，以更高標準統一公司與股東利益，在釋放增長潛力的同時，為投資者創造長期穩定回報。2025 年 11 月，公司成功納入 MSCI 全球小型股指數，進一步進入全球被動及主動型基金視野，吸引更廣泛的國際投資者關注。未來展望：三大超級戰略領航，錨定長期高質量發展美麗田園集團的長期願景是成為中國美與健康的領航者。站在行業整合與品牌升級的新起點，2025年11月，美麗田園正式發佈超級品牌、超級連鎖、超級數字化三大戰略，為未來高質量發展指明方向，擘畫長期發展藍圖。超級品牌，構建美與健康品牌矩陣。我們持續升級專業實力，打造超越客戶期待的體驗，重塑美容行業價值新空間。同時，積極參與並推動行業標準制定，將美麗田園的高標準上升為行業共識，提升消費者信任與品牌價值。超級連鎖，我們將發揮「雙美+雙保健」商業模式優勢，通過內生增長與外延並購雙輪驅動戰略帶動公司價值躍升。我們致力於打造20個收入過億的核心城市，同時構建自有供應鏈能力，融合全球精選與聯合專研，為中國高線城市女性提供兼具專業性、個性化、高品質的美容和消費醫療產品與服務。超級數字化，我們致力於打造數智化與AI系統基礎建設，構建數智化驅動的企業管理體系，打造數智引領的美與健康服務連鎖標杆企業。結語未來，美麗田園將繼續堅守「以客戶為中心」的初心，依託「美麗田園商業系統」，以「三大超級戰略」為指引，在不斷滿足高線城市女性對美與健康的多元需求的同時實現立體增長，推動中國美與健康行業的高質量發展。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績摘要：- 截至2025年12月31日止年度收益約為37.4億港元, 同比增加約11.1%。- 截至2025年12月31日止年度毛利率約為55.8% ；毛利約為20.8億港元，同比增加約15.9%。- 截至2025年12月31日止EBITDA 約為9.4億港元，同比增加約32.4%。- 本集團於截至2025年12月31日止純利約為6.0億港元，同比增加47.7%。- 截至2025年12月31日止每股基本盈利約為63.7港仙，相較去年同期增加約47.5%。- 董事會建議宣派截至 2025年12月31日止年度末期股息每股普通股15.0港仙。- 截至2025年12月31日止年度，本集團於中國內地、泰國及越南生產設施生產之數碼化解決方案個案增加至約1,039,000件，較2024年同期增加32.7%，原因為更多客戶採用口腔內部掃描器。香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 2026年3月26日，全球領先之義齒器材供應商 - 現代牙科集團有限公司 (簡稱「現代牙科」或「本集團」，股份代號：03600.HK) 欣然公佈截至2025年12月31日止年度(「年度」) 業績。截至2025年12月31日止年度，在牙科行業數碼化趨勢持續的支持下，本集團的多維度策略及持續提升的營運效率及生產力，使其於本期間的收益、純利及EBITDA數字均創下紀錄新高。雖然期內宏觀經濟環境充滿挑戰，牙科手術的需求普遍疲弱，且貿易戰存在不確定性，然而仍然創下紀錄。本集團利用位於泰國、越南及中國內地的國際生產設施，積極應對前所未有的國際貿易環境。全球數碼化趨勢持續推動義齒行業的整合，使本集團進一步擴大其市場份額。我們持續的數碼轉型措施提升客戶及病人體驗的同時，進一步使本集團在競爭對手中脫穎而出，表現優於同業。本集團的相關基礎仍然穩固，並將全力以赴把握未來機遇。歐洲市場業務截至2025年12月31日止年度，歐洲市場錄得收益約18.9億港元，較去年增加約2.7億港元，此地理市場佔本集團收益總額50.5%。歐洲市場收益增加主要由於新產品的推出(例如數碼化義齒)及我們最先進的數碼化流程，推動銷售訂單量增加。本集團已成為提供全面數碼化解決方案的先驅，範圍涵蓋多項微創及美容義齒解決方案以至口腔內部掃描儀及透明矯正器，本集團已準備好把握牙科行業數碼化趨勢加速帶來的機遇。本集團繼續透過所建立，重點為教育及數碼化且非常鄰近客戶的牙科生態系統解決方案，積極從國際及本地競爭對手取得市場份額；透過不同的境內及境外資源有效地滿足我們客戶的高期望。本集團一直致力並將繼續裝備好自己，為市場上的牙科領域提供最先進的數碼化解決方案。北美市場業務於截至2025年12月31日止年度，北美市場錄得收益約7.0億港元，較去年減少約5,570萬港元，此地理市場佔本集團收益總額約18.6%。我們在北美地區的大部分業務包括MicroDental Laboratories, Inc.及其附屬公司(「MicroDental集團」)在本地製造的高端產品。雖然2025年對主動美容治療的需求仍然疲弱，然而我們的中央化數碼流程及對區內廣泛生產單位的網絡讓我們為北美客戶交出更高服務質素及營運效率。我們位於美國、中國、越南及泰國等地的多元化供應基地，繼續在應對美國關稅的不確定性時帶來更大彈性－此為將我們與競爭對手作區分的優勢。雖然進口產品線的數碼化帶動大型市場個案的增長，然而2025年4月在美國實施的關稅帶來新的不確定性及為我們以進口為主的業務單位的銷售帶來緩慢增長。大中華市場業務截至2025年12月31日止年度，大中華市場錄得收益約6.2億港元，較去年減少約4,685萬港元，此地理市場佔本集團收益總額約16.5%。中國內地市場面對帶量採購政策及價格激烈競爭延長的逆境，而於2025年下半年情況開始穩定。此亦導致中國內地牙科診所積極於香港推廣種植牙治療(香港患者就診人數明顯減少)。本集團有意退出低利潤分部，並專注於中及高價值客戶，確保本集團業務能夠長期及可持續獲利。本集團對此市場的中長期前景感到樂觀，特別是在政府最新的採購相關措施中，預計(i)規範義齒價格及建立價格透明度，平衡中心點；(ii)讓本集團領先的品牌名稱及聲望成為客戶及顧客的主要考量；及(iii)讓本集團從其龐大生產團隊中得益及根據顧客或客戶有效分配資源的能力。澳洲市場業務截至2025年12月31日止年度，澳洲市場錄得收益約2.9億港元，較去年增加約2,438萬港元，此地理市場佔本集團收益總額約7.7%。澳洲的收益錄得增長，反映牙科行業數碼化趨勢帶動大量新的數碼化產品，以及收購Digital Sleep的收益貢獻，但部分被相較於截至2024年12月31日止年度，澳元兌港元貶值2.4%所抵銷。透過我們不同的品牌(可提供境內及境外製造的產品)，憑藉涵蓋從經濟及標準至優質/精品等的多種價位，本集團能夠有效地滲透整個澳洲市場。我們投資於本地產能，以為客戶提供更快捷的服務，並可供選擇產品之生產地。本集團為澳洲市場最大參與者之一並為市場內主要企業牙科團體的首選供應商。其他市場其他市場主要包括泰國、印度洋國家、馬來西亞、台灣及新加坡。截至2025年12月31日止年度，該等市場錄得收益約2.5億港元，較截至2024年12月31日止年度增加約1.8億港元。此地理市場佔本集團收益總額約6.7%。其他市場的收益增加主要由於新收購的Hexa Ceram帶來的收益貢獻所致。未來前景及策略全球宏觀經濟環境仍然不明朗，地緣政治的緊張局勢及關稅的潛在變動繼續營造不利環境。然而，本集團的生產遍及全球各地，而全球分銷網絡讓我們在面對該等挑戰時享有獨特優勢。有別於依賴單一國家生產的一眾競爭對手，我們的營運遍佈中國、越南及泰國(包括新收購的Hexa Ceram)等地，讓我們面對挑戰時能夠進退有據，靈活應變。此策略連同我們快速適應當地市場環境的能力，使本集團降低風險，同時把握各地區的新興機遇。牙科行業繼續展現卓越的適應力，在不可逆轉的人口趨勢下加以突顯，包括人口老化及人們對口腔健康的意識提高，持續帶動義齒的長期需求。本集團建基於2025年創記錄的表現而處於有利位置，能夠保持良好勢頭，同時進一步強化市場的領導地位。行業數碼化勢不可擋，加快義齒行業的整合。我們處於轉型的尖端，目前數碼化解決方案個案佔總銷量約35至40%。我們的中央化數碼工作流程、有關口腔內部掃描儀的夥伴關係、專有的解決方案及全球教育中心有助提升營運效率、縮短處理時間及提供卓越的客戶體驗。有關措施創造高進入門檻，並將於未來數年繼續擴大利潤及增加市場份額。在成功整合於2025年1月收購的泰國最大牙科實驗室Hexa Ceram及Digital Sleep Design(用於治療阻塞性睡眠窒息症的專利尼龍口腔矯正器)後，我們在東南亞地區的影響力及專業能力已經大幅提升。是次擴張連同我們位於美國、中國、越南及泰國等地的多元化供應基地，讓我們在應對潛在的貿易及其他地緣政治風險時帶來更大彈性，同時支持區內快速交付。展望將來，本集團仍然致力透過多角度方針強化其全球領導地位。我們將繼續尋求具針對性的收購、合營企業及夥伴關係，以擴大及補充我們所提供的產品，特別是我們高增長的透明矯正器TrioClear，同時加強我們的分銷及銷售網絡。我們在大型生產設施、AI、自動化、研發及數碼創新方面的持續投資，使效率大幅增高，從而確保我們一直處於行業尖端。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問，專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材，例如牙冠及牙橋；活動義齒器材，例如活動義齒；及其他器材，例如正畸類器材、透明牙套、運動防護器及防鼾器。 現代牙科集團擁有多個備受稱許的全球品牌，包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental、澳洲及新西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、臺灣的 Modern Dental TW、馬來西亞的 Apex Digital Dental及泰國的Hexa Ceram等。我們提供穩定和優質的產品及卓越的客戶服務，令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 35,000 名客戶。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

摘要：- 總訂單金額約為人民幣3,955.0百萬元，較同期的約人民幣3,505.9百萬元增加約12.8%。- 總收益約為人民幣3,430.1百萬元，較同期的約人民幣2,306.0百萬元增加約48.7%。- 股東應佔溢利約為人民幣921.8百萬元，較同期的約人民幣272.4百萬元增加約238.5%。- 非香港財務報告準則下經調整年內溢利（剔除以股份為基礎的薪酬開支）約人民幣1,022.5百萬元，較同期的約人民幣350.5百萬元增加約191.8%。- 董事會建議派發末期股息約168.5百萬港元，即每股0.36港元（現金），建議末期股息須待股東於股東週年大會上審議及批准。香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 九方智投控股有限公司（「九方智投控股」或「公司」；及其附屬公司統稱「本集團」或「我們」）欣然宣佈截至2025年12月31日止年度（「2025年」或「報告期內」）之綜合年度業績。報告期內，本集團踐行「科技＋投研」雙輪驅動戰略，錄得良好業績表現。基於強勁的現金流與盈利表現，董事會建議派發末期股息每股0.36港元，連同已派發的中期股息，全年累計派息總額約407.4百萬港元，積極回報股東支持。財務表現強勁 盈利能力大幅提升報告期內，本集團持續推進產品創新、AI應用及投研能力建設，帶動整體業務穩健增長。年度總收益達人民幣3,430.1百萬元，同比增長48.7%；毛利達人民幣2,821.0百萬元，同比增長48.9%，毛利率維持在82.2%的高水平，反映本集團業務模式具備良好的規模效益及盈利質量。盈利表現方面，股東應佔溢利同比大幅上升238.5%至人民幣921.8百萬元。若剔除以股份為基礎的薪酬開支，按非香港財務報告準則計算的經調整年內溢利達人民幣1,022.5百萬元，同比增長191.8%，顯示公司戰略執行持續見效，並具備良好的市場應變能力。本集團始終重視股東回報，建議派發2025年度末期股息每股0.36港元，派息總額約168.5百萬港元。連同已派發的中期股息約238.9百萬港元，本集團2025年全年派息總額約為407.4百萬港元。穩健的派息政策充分反映集團充裕的現金儲備，以及對未來發展前景的堅定信心。持續優化產品矩陣 推動多元化服務體系建設報告期內，本集團持續構建多元化產品矩陣，圍繞不同客群需求不斷豐富產品組合。VIP產品（股道領航、超級投資家）穩步迭代，新增多款量化及AI產品，並上線7×24小時AI智能客服，進一步提升服務效率；直播體系亦全面升級，場次同比增加36%，日均總UV超過10萬。依託「硬件＋AI＋內容＋服務」一體化方案，「易知股道」AI股票機於報告期內淨銷量超7.5萬台，用戶使用時長及黏性均保持良好水平；「九爻股」累計推出80餘款輕量化產品，將專業投研能力轉化為標準化產品，有效降低個人投資者參與門檻；「九方智投APP」則實現由工具向平台的戰略轉型，報告期內月活用戶同比增長超40%，30日留存率維持在50%以上，整體用戶黏性持續提升。此外，本集團進一步完善產品矩陣，推出「決策大師」及「星級服務」兩大新產品，填補中端產品空缺，跑通交易鏈路。其中，「決策大師」聚焦AI＋題材、價投及量化三大投研模組，協助個人投資者提升自主決策能力；「星級服務」則聯動券商及合作夥伴，打造「工具—服務—交易」一體化生態閉環，報告期內服務用戶規模超過5萬。以科技創新為核心 全力邁向「投顧智能體2.0」本集團視創新和技術研發為核心驅動力，全速推進全面「數智化」戰略，深耕證券領域「人工智能+」應用，全力邁向「投顧智能體2.0」時代。報告期內，研發投入約人民幣356百萬元，研發人員達624人，較同期增長約42.8%；在人工智能、大數據及產品功能等領域共擁有軟件著作權及專利158件，同比新增22件。自研的「九方靈犀」大模型助手V3.0通過中國信息通信研究院大模型助手功能完備性測試，成為證券行業首個獲此認證的大模型應用。報告期內，該產品服務客戶約66.4萬人，累計服務達2,258萬次；智能投顧數字人「九哥」服務客戶約60萬人，累計服務超1,900萬次。公司亦推出診股智能體4.0智能體工具、AI小策問答助手，構建了覆蓋業務全流程的智能合規風控平台，逐步將AI能力深度賦能各大業務核心場景並形成規模化應用。為進一步強化技術基礎，本集團設立科技子公司九方智擎並入駐全國首個大模型創新生態特區「模速空間」，作為集團AI技術核心載體，搭載原生服務技術體系，推動AI在投研、投教、風控等場景深度落地。以深度投研為基石 堅持買方投顧 深化「1+N」投研體系本集團持續深化「1個研究所，N條業務線」投研體系，以九方金融研究所為投研中樞，推動專業能力滲透至業務全流程。研究所目前已建立以首席經濟學家肖立晟博士為核心，聯動4名專家、8名超級IP及128名專業人員組成的金字塔式團隊。截至報告期末，本集團擁有576名具備證券投資顧問資格及2,628名具備證券業資格的員工，專業團隊規模及結構均保持行業領先。報告期內，研究所完成上市公司、行業論壇及券商策略會等調研超300場，研究覆蓋約2,000家上市公司，並深度跟蹤其中1,500家；全年累計撰寫約1,200篇深度報告，並開發45套專題課程，總時長達2,000分鐘，持續鞏固買方投顧專業能力。多維全域流量運營 拓展業務增長新維度本集團以AI技術為核心驅動力，將MCN精細化流量運營定位為連接用戶與業務的核心樞紐，構建「公域MCN＋私域＋自有APP」三位一體、協同聯動的全域流量體系。技術層面，公司深度應用AIGC重構內容生產，從人工創作轉向「人機協同」，並搭建起「投放數據－模型訓練－運營自動化」的數據飛輪。報告期內，本集團持續鞏固線上短視頻直播平台的領先運營優勢，搭建多平台協同流量矩陣，打造多層次優質內容生態。同時創新探索AI股票機電商模式與APP應用市場，推動流量運營與產品特性深度適配。展望未來九方智投控股董事會主席及首席執行官陳文彬先生表示：「2025年，我們始終堅持『科技＋投研』雙輪驅動策略。我們不僅實現了業績的跨越式增長，更成功引領行業邁向『投顧智能2.0』時代。基於人工智能與大數據技術，我們研發了九方智能投顧數字人、九方靈犀、九方智研等AI產品，實現了行業領先的創新實踐與場景應用，助力用戶完成從『認知提升』到『決策優化』的關鍵轉化。同時，我們將專業的投研能力轉化為觸手可及的輕量化服務，實現了由『工具向平台』的戰略轉型。我們貫徹理性投資、價值投資和長期投資理念，幫助客戶構建正確的投資觀。未來，本集團將聚焦四大戰略維度：第一，深化AI全場景賦能，加速投顧智能體迭代與C端商業化落地，驅動公司全面數智化轉型；第二，充分利用方德證券、方德資本牌照資源優勢，深化全球化戰略佈局，輸出九方核心模式，加速海外業務拓展，並推進數字資產相關牌照升級與戰略投資，完善數字資產基礎設施搭建；第三，強化產品力驅動多元協同，深化與券商等持牌金融機構的合作，構建涵蓋投前、投中、投後的服務閉環；第四，持續優化客戶經營體系，透過全域化流量佈局深挖流量價值，實現客戶長效留存。我們致力于让投資理財變得更簡單、更專業、提升投资理财的幸福感。」關於九方智投控股有限公司九方智投控股有限公司作為新一代股票投資助手，面向廣大個人投資者提供股票投資工具、證券投資顧問、投資者教育等服務，相繼推出股票行情軟件、AI股票機、股道領航、超級投資家、九爻股等產品。該公司通過「科技＋投研」模式，基於人工智能（AI）與大數據技術研發九方智能投顧數字人、九方靈犀、九方智研等AI產品，實現行業創新實踐與場景應用。如有垂詢，請聯絡：金融公關（香港）有限公司電郵：ir@financialpr.hk電話：852 2610 0846傳真：852 2610 0842 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 近日，2026中關村論壇年會在北京隆重舉行。作為國家級科技創新交流合作平臺的重要參與者，百望股份受邀出席本次國家級科技創新交流盛會，並在"東盟創新合作發展論壇"中發表了重磅主題演講。論壇上，百望股份聚焦跨境貿易合規痛點，推介全球智能稅務合規平臺Tax Swift。它內置百望自研的AI稅務引擎、百望指數與國家適配器，依托覆蓋全球的稅務規則知識庫，動態監控、AI分析、自動更新，打造起全球貿易的"合規路由器"，為國際經貿合作注入合規新動能。論壇聚焦科技創新，跨境合規成全球貿易核心命題2026年中關村論壇年會，是經國務院批准、以"科技創新與產業創新深度融合"為年度主題，由科技部、國家發展改革委、工業和信息化部、國家國資委、中國科學院、中國工程院、中國科協和北京市政府共同主辦。大會匯聚了100多個國家和地區的全球頂尖科學家、企業家及國際組織代表，上千名嘉賓共同搭建起中國與世界科技創新交流的橋梁。作為本次中關村論壇的重要平行論壇，東盟創新合作發展論壇聚焦中國與東盟科技創新協同、產業融合發展、跨境貿易便利化等核心議題，匯聚東盟各國政、產、學、研各界代表，交流研判破解區域經貿合作中的共性難題。在主題演講環節，百望股份圍繞著"AI賦能中企出海：構建全球化合規新底座"展開了深度分享。當前，全球貿易一體化進程不斷加快，跨國經營的業務蓬勃發展，但稅務合規難題始終是制約全球貿易高效推進的關鍵瓶頸。尤其是東盟這樣的活力經濟體，區域內各國經貿往來頻繁，跨境交易規模持續攀升，市場主體對於交易效率、交易合規有著更高的需求和更迫切的期待，而區域內各國稅務政策、技術標准的差異，卻成為了制約中國-東盟跨境貿易提質增效的重要因素。從實踐來看，國際貿易稅務合規難題呈現多元化、複雜化態勢：- 語言與格式壁壘凸顯，不同標准、規範讓企業票據解讀成本高、理解易出偏差；- 各國財稅政策碎片化嚴重，差異性的稅種、稅率、申報流程，讓企業難以精准掌握；- 技術標准不統一，系統接口、數據傳輸缺乏規範，各類操作繁瑣且效率低下；- 跨境交易鏈條長、涉及主體多，企業難以實現全流程風險檢測；這些難題不僅增加了企業跨境經營的成本，更成為制約企業融入全球產業鏈、拓展國際市場的關鍵瓶頸。百望股份的Tax Swift平臺，正是破解合規困境、保駕跨境貿易的全新技術創新，尤其為中國-東盟跨境貿易合規發展提供了高效可行的思路。Tax Swift重磅亮相，全鏈路一站式賦能國際貿易合規作為百望股份的深耕全球稅務合規領域、布局國際化市場的核心成果，Tax Swift一次適配，就可幫助企業構建起覆蓋"票據處理-納稅申報-風險管控"的全鏈路跨境稅務合規服務體系：一是全球AI全鏈路票據處理能力，可打破語言與格式壁壘。國際化引擎、發票引擎、稅務引擎與國家適配器，四重引擎自動協同運轉，完成智能算稅、智能識別等，一套架構適配全球業務場景。企業無需手動幹預任何細節，即可完成多語言、多幣種、多時區的票據管理工作，完美適配東盟各國票據規範與業務場景。二是全球AI一鍵申報，打通跨境稅務申報便捷通道。Tax Swift現已與20多國國稅局直連，全球稅務規則知識庫動態更新、AI分析引擎自動掃描規則變化，聯動發票識別引擎與全球交易計稅規則引擎實時響應，將全球申報工作壓縮成一個動作：一鍵登錄，自動填飽，實時同步狀態，可大幅提升東盟跨境貿易稅務申報效率。三是全球AI稅務顧問，提供全周期政策支撐。平臺內置超3萬條國際財稅規則，覆蓋200+國家稅種與費金，通過實時聯動發票引擎與稅務引擎，實現AI自動解讀、自動更新，及時識別和處置異常變化，幫助企業精准把握區域政策動態、規避合規風險，尤其針對東盟各國稅務政策的更新與調整實現實時響應。三大AI能力模塊的協同運作，為企業建立起全球合規洞察的能力，構築起清晰可控的合規管理邊界。當前，全球貿易格局深度調整，合規已成為企業跨境經營的核心競爭力，百望股份"貿易無國界、納稅有主權"的理念，精准契合了出海企業的合規需求。依托全球化戰略布局，百望股份持續推進TaxSwift產品迭代落地，自2025年8月啟動以來，產品已完成1.0版本全球電子發票布局，並在2026年加速海外數據中心與算力中心部署，加速東南亞、歐盟、中東等區域市場的拓展，向著建設覆蓋80+CTC國家的全球AI票稅合規平臺快速演進。而東盟作為百望股份全球化出海的先鋒陣地，憑借區域內旺盛的跨境貿易合規需求，成為 Tax Swift 落地應用的核心市場，已有眾多企業與百望股份達成深度合作，其中越南、新加坡、印度尼西亞等東盟國家的企業、高校更是與百望攜手，共同探索跨境稅務合規的數智化解決方案，讓 Tax Swift的技術能力與服務體系更好地適配東盟市場需求。依托中關村論壇及東盟創新合作發展論壇的開放平臺，更多國際嘉賓尤其是東盟各國代表，對百望股份的數智解決方案有了進一步了解。深耕財稅數智領域十餘年，百望股份已經累計處理發票數量逾260億張，對應交易總額高達1188.0萬億元，服務的納稅人識別號數量更是突破了9640萬家，這些豐富的實踐經驗與數據智能領域的深厚沉澱，贏得了與會嘉賓產生了高度關注與廣泛認可。未來，百望股份將持續深化Tax Swift平臺的迭代升級，重點打磨適配東盟市場的產品能力與服務體系，打造一流的全球稅務合規智能體平臺，進一步拓展全球服務範圍，幫助更多跨境經營的國際企業開拓發展、贏得未來！ Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%, increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – CALB (03931.HK) rolled its pioneering 'R46 cylindrical battery' system off the production line at the Chengdu factory on March 25, an aviation power battery set to power the XPENG ARIDGE X3-F Land Aircraft Carrier flying car. The recently unveiled R46 cylindrical battery technology boasts an energy density of 360 Wh/kg, the highest-density solid-liquid hybrid cylindrical battery in the industry. It achieves an exceptional balance between high safety, high power density and high energy density, meets aviation-grade safety standards, and will be equipped in several of ARIDGE's flying car models.The partnership between the two parties began in 2022, with CALB assisting ARIDGE in completing the world’s maiden flight of an electric vertical take-off and landing (eVTOL) flying car. Following rigorous validation, the reliability of CALB’s battery product has been fully verified. Building on this momentum, CALB assembled a team of top researchers to focus on the next-generation advanced R46 cylindrical battery system, tasked with addressing a range of scientific and technological challenges.Taking the lead in collaborating with leading institutions including ARIDGE, CALB has been awarded support by the National Key R&D Program Project, further positioning the technologies at the forefront of global innovation in intrinsic safety and high-specific-energy aviation power batteries. Consequently, the two parties signed a deepened strategic cooperation agreement in April 2025, establishing an exclusive supply relationship for next-generation models.From leading the National Key R&D Program focused on advanced R46 cylindrical battery system technology to achieving the mass production of flying car batteries, CALB is accelerating its expansion into forward-looking emerging sectors. The company's commercialization capability across diversified application scenarios continues to strengthen, opening new growth opportunities in the competition for next-generation energy technologies. CALB Group Co., Ltd. https://en.calb-tech.com/ [03931.HK] Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- 华堂宁(R)全年銷量超400萬盒，同比增長91%，銷售額達4.929億元，同比增長93%，公司全面自主商業化運營成效卓著。- 實現創紀錄盈利，稅前盈利達11.064億元；現金餘額穩健，截至年末達 10.923億元，為持續運營發展奠定堅實基礎。- 毛利率提升至56.9%，銷售開支占比從59.9%優化至33.6%，盈利能力顯著增強。- 华堂宁(R)原價續約新版醫保目錄，2026-2027年維持2025年的價格不變，臨床價值和創新價值再獲認可。- 隨著PTE獲批，中國市場獨佔權獲5年延期至2034年4月，商業確定性進一步提升。- 多格列艾汀（HYHOMSIS(R) ，華領片(R)）獲得香港地區上市批准，加速其面向東南亞的全球擴張進程。- 發佈多項真實世界證據，證實多格列艾汀治療優勢。- 持續拓展血糖穩態治療潛力，啟動多項全新的疾病首創新適應症研究，研究範圍涵蓋糖尿病預防、罕見病、輕度認知障礙及衰弱症領域。上海, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年12月31日止年度（「報告期」）經審核的綜合業績。報告期內，公司核心產品、全球首創抗糖尿病新藥、葡萄糖激酶激活劑（GKA）华堂宁(R)（多格列艾汀片）實現全方位推進，公司自主商業化團隊於運營首年即實現高效組建和運轉，研發管線持續豐富，財務表現實現歷史性突破，成功邁入盈利新階段，為全球糖尿病治療領域的創新發展注入強勁動力。華領醫藥創始人、CEO陳力博士表示：「2025年是華領醫藥商業化運營中的意義非凡的一年。公司成功完成從研發驅動型組織向商業化驅動型組織的轉型，具備了全球首創新藥、血糖穩態調節劑华堂宁(R)的完全自主商業化運營能力。憑藉強勁的市場執行力與產品競爭力，相較於2024年將商業化業務委託給營銷合作夥伴的階段，公司的銷量與營收實現了近三位數的增長。與此同時，通過推動多格列艾汀在香港的註冊工作，公司在全球市場拓展方面取得了關鍵性進展，我們將向覆蓋7億人口的東南亞地區進行市場佈局。我們持續拓展血糖穩態調控技術的臨床應用場景，積極佈局早期阿爾茨海默病、衰弱症等新適應症領域。針對GCK-MODY及衰弱症開展的疾病首創新藥研發工作，將為華領醫藥未來五年的創新發展劃定全新方向。」業務亮點與運營進展- 商業化全面發力，盈利實現歷史性突破2025年1月1日起，公司正式全面接管华堂宁(R)在中國的商業化工作，獲得全部運營與戰略主導權，公司成功搭建了專業的銷售團隊，覆蓋全國10個銷售區域，專注於產品營銷、醫學事務及商業運營。通過人工智能賦能的數字商業化平台，運營效率與銷售生產力大幅提升，為公司商業化發展注入新活力。受益於國家醫保藥品目錄的持續廣泛覆蓋，华堂宁(R)在二級和三級醫院的處方量顯著增長，患者可及性不斷提高，通過3000多家醫院、社區衛生中心、藥房和線上渠道，惠及超過50萬名患者。報告期內，產品銷量達401.1萬盒，同比增長91%；銷售額達4.929 億元，同比增長93%，在單價保持穩定的情況下，充分印證了市場需求的強勁增長和自主商業化團隊的高效執行能力。盈利能力方面，2025年，公司毛利達到2.804億元，同比增長125%，得益於生產規模擴大及製造工藝優化，公司毛利率從2024年的48.7% 提升至56.9%，增加8.2個百分點；銷售開支僅增長1230萬元至1.655億元，占收入比例優化至33.6%，較2024年的59.9%大幅下降；商業化業務實現約1.149億元盈利（按毛利扣除銷售開支計算）。公司預期仍將持續擴充商業化團隊規模，但商業化運營的盈利趨勢也將持續增長。在2024年底終止與拜耳合作後，多格列艾汀銷售額創歷史新高，報告期內，公司稅前盈利增加至人民幣11.064億。截至2025年末，現金結餘約為人民幣10.923億元，穩健的現金情況為公司持續發展奠定了堅實基礎。- 全球佈局加速推進，核心權益得到強化公司全球化佈局邁出關鍵步伐。2026年2月27日，多格列艾汀（香港地區商品名：MYHOMSIS(R)，華領片(R)）成功獲得香港監管機構的上市批准，公司計劃2026年中正式在香港市場推出該產品，並將進一步向亞洲地區拓展。此外，公司已于2025年向澳門藥監局遞交華領片(R)（MYHOMSIS(R)）的新藥上市申請。公司在知識產權保護方面也再獲進展。2026年2月，中國國家知識產權局批准多格列艾汀專利期限補償（PTE）申請，核心專利保護期延長至2034年4月，新增5年市場獨佔權，為產品長期市場競爭提供有力保障。2025年，多格列艾汀獲中國監管機構認定為國家級創新藥及慢病有效治療藥物，國家醫保局已確認，2026-2027年，华堂宁(R)的國家醫保目錄價格維持不變，公司將持續保障產品的市場競爭力和患者可及性，尤其在二級和三級醫院，加速患者的用藥普及。- 真實世界研究推進，臨床價值獲持續驗證真實世界證據（RWE）研究持續佐證多格列艾汀在葡萄糖依賴性胰島分泌功能改善中的關鍵作用，並顯示其在糖尿病預防、緩解及延緩或預防糖尿病併發症方面的功效。HMM0701已完成入組，共招募380名2型糖尿病患者。2025年6月，在美國ADA年會上發表的中期分析結果顯示，86%的患者同時服用兩種或以上降血糖藥物，41%的患者使用胰島素。經6個月治療後，血糖控制明顯改善，糖化血紅蛋白由8.1%降至7.3%，平均TIR（目標範圍內時間）提升至70%以上。迄今為止的研究顯示，多格列艾汀與其他降糖藥物聯合使用時，患者的餐後血糖水平和β細胞功能均顯著改善。另外，在美國進行的多格列艾汀機制研究（採用雙示蹤劑測量法），為平均確診糖尿病17年的2型糖尿病患者的肝糖原生成提供了科學證據。在該研究中，患者每日服用兩次多格列艾汀，持續6周。結果顯示，多格列艾汀能增加葡萄糖直接流入肝糖原的通量，意味著其有助於恢復肝臟GK功能。結合臨床研究數據顯示，多格列艾汀可改善早期胰島素釋放和GLP-1分泌，恢復2型糖尿病患者的肝臟GK功能，不僅為控制餐後血糖波動提供重要途徑，並在控制糖尿病併發症（如糖尿病腎病變及輕度認知障礙）方面提供獨特契機。HMM0601研究已經完成臨床試驗，共納入2000名受試者，平均患病時間為7.9年，其中超過30%患病時間超過10年。初步結果顯示，多格列艾汀在中國2型糖尿病患者中安全性、耐受性良好。研究中未觀察到新的不良反應，不良反應發生率維持在III期臨床試驗中觀察到的低水平，患者的用藥依從性普遍較高，平均依從率約為95%。在本研究中，80%的受試者已使用一種或多種口服降血糖藥，20%的受試者使用胰島素。多格列艾汀不僅在整體患者群體中展現出良好的療效及安全性，在老年、肥胖及高血糖患者群體中同樣有效，無論作為單藥治療或與二甲雙胍、SGLT-2抑制劑、胰島素及其他藥物聯合使用。頂線結果將於2026年ADA年會上發表。- 臨床研發持續深化，新適應症不斷拓展多格列艾汀用於治療MODY-2患者。中國內地及香港地區醫學專家已獨立開展多格列艾汀用於MODY-2治療的臨床研究及臨床前研究。MODY-2（又稱GCK-MODY）是一種單基因疾病，患者因葡萄糖激酶基因(GCK)存在遺傳缺陷，導致血糖升高及第二時相胰島素釋放顯著減少。在中國，MODY-2患者群體規模約為170萬人。此類患者確診糖尿病時年齡偏小，且由於現有治療藥物療效不佳，這一患者群體存在未被滿足的醫療需求。中國研究人員在針對MODY-2患者的臨床研究中報告指出，對於先前使用二甲雙胍、TZD、DPP-4抑制劑及SGLT-2抑制劑仍無法控制高血糖的MODY-2患者，多格列艾汀能有效將血糖降至正常水平。其他結果顯示，單劑量多格列艾汀可顯著改善這類患者的整體葡萄糖敏感性及第二時相胰島素分泌，表明多格列艾汀具有調節GLP-1分泌的獨特作用機制。基於以上結果，華領醫藥已與國家藥品監督管理局（NMPA）藥品審評中心溝通，將於2026年提交多格列艾汀用於MODY-2患者的IND申請。多格列艾汀用於糖尿病預防。糖尿病預防是華領醫藥的重要研發重點。公司已於香港啟動針對糖尿病前期糖耐量異常（IGT）受試者及早期糖尿病患者的SENSITIZE 3臨床研究。這項雙盲安慰劑對照研究將評估受試者在靜脈葡萄糖耐量試驗及口服葡萄糖耐量試驗下的血糖控制及胰島功能，以更明確界定臨床治療基線及終點指標。我們預計於2026年完成研究後，將在中國及亞太地區探索提交多格列艾汀用於糖尿病預防的IND申請的新機遇。多格列艾汀用於神經退行性疾病。研究顯示，中國老年人的輕度認知障礙患病率約為15.5%，美國則約為22%；該症狀在2型糖尿病患者中也相當常見，發病率達45%。多格列艾汀用於神經退行性疾病的研究已成為公司藥物研發工作的新焦點。通過全基因組關聯分析(GWAS)及孟德爾隨機化（MR）研究，我們發現GK基因激活在預防人類記憶力衰退及認知障礙方面具有重要作用。同時我們也發現，餐後血糖波動與阿茲海默症及失智症密切相關。血糖穩態異常及糖尿病狀況會導致大腦葡萄糖轉運蛋白及胰島素受體表達減少，而低劑量多格列艾汀可預防該功能損傷。我們已確認多格列艾汀在治療輕度認知障礙方面的潛在價值，並將於未來啟動針對該疾病領域的首創療法的相關臨床研究。多格列艾汀用於治療衰弱症。衰弱症是一種與年齡相關的老年綜合症，其特徵為對內外應激因子的耐受性降低。約17%的美國人及11%的亞洲人（50歲以上）患有衰弱症，而處於衰弱症前期者則分別約占此兩個群組的50%及47%。衰弱症並非單一器官疾病，而是多系統內穩態失調所導致的後果。遺傳學證據支持GK激活對降低衰弱症風險具有因果作用。我們計劃於未來啟動臨床研究，以推進多格列艾汀在衰弱症治療領域的應用。聯合用藥用於糖尿病及併發症的治療。臨床與基礎研究結果顯示，多格列艾汀能恢復胰腺在葡萄糖刺激下的胰島素及GLP-1分泌，也可以通過恢復2型糖尿病患者肝臟葡萄糖激酶功能，改善肝臟胰島素敏感性並降低肝臟胰島素抵抗。多格列艾汀與DPP-4抑制劑、SGLT-2抑制劑及GLP-1受體激動劑的聯合使用已證明可有效調節脂質代謝，與抗癌PI3K抑制劑聯合使用的研究也為血糖穩態管理帶來獨特優勢。- 產品管線豐富多元，創新佈局未來增長華領醫藥在核心產品基礎上持續豐富管線佈局。依託多格列艾汀與二甲雙胍聯合用藥在III期臨床試驗和真實世界應用中取得的優異數據，公司加速推進多格列艾汀與二甲雙胍固定複方製劑（FDC）的研發。該製劑為每日兩次給藥方案，適用于單用二甲雙胍血糖控制不佳的2型糖尿病患者，旨在以進一步提升患者的用藥依從性。公司已向NMPA提交IND申請文件。此外，GMP商業化生產工藝也已成功開展，為2027年新藥上市申請的關鍵生物等效性研究做好準備。臨床研究顯示，多格列艾汀與二甲雙胍聯用能夠更好地控制血糖，降低餐後血糖，改善空腹血糖，為優化血糖穩態終點提供了新的臨床價值。第二代GKA的研發取得重要突破。作為肥胖2型糖尿病患者每日一次治療的緩釋新片劑，公司已在美國啟動多格列艾汀多劑量遞增（MAD）研究，以探討第二代GKA在血糖穩態控制方面的療效及新藥的作用機制，首例患者已於2025年12月入組，預計2026年中公佈頂線數據。同時，公司還在探索多格列艾汀與GLP-1受體激動劑、SGLT-2抑制劑等藥物的聯合治療方案。近期，在一項中國的臨床試驗中，研究者報告：多格列艾汀聯合司美格魯肽治療12周，療效顯著優於司美格魯肽單藥治療。聯合治療組在血糖控制、體重相關指標及β細胞功能等多項關鍵指標上均表現更優。財務摘要截至2025年12月31日，- 华堂宁(R)全年銷量約401.1萬盒，相較2024年全年，同比增長91%，實現營收約4.929億元，同比增長93%。- 毛利約人民幣2.804億元，同比增長125%，毛利率提升至56.9%；- 稅前盈利約人民幣11.064億元，較2024年增長542%；- 銀行結餘及現金約人民幣10.923億元，資金狀況穩健；- 總開支約人民幣4.334億。前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。2026年2月，多格列艾汀（商品名：MYHOMSIS(R)，華領片(R)）獲得中國香港特別行政區政府衛生署藥物辦公室的上市批准。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關信息的，特別是標識或要求，應遵循中國監管機構批准的相關文件。另外，相關信息不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – 26 March, Unisound (09678.HK) announced its audited annual results for the year ended December 31, 2025. As the Company's first annual results announcement since listing, it underscores strong growth momentum and continued improvement in its financial profile.Revenue Mix Continues to Improve, with Faster Growth in H2For the full year of 2025, Unisound achieved total revenue of $175 million, representing a year-on-year (YoY) increase of 29%. Revenue in the second half of the year increased by 33% YoY to $117 million.It is worth noting that the Company's large language model (LLM) business generated a full-year revenue of $88.43 million, surging by over 10 times YoY. In particular, this business contributed approximately $72.49 million in H2 revenue, five times the level recorded in H1, demonstrating a compelling capacity for large-scale commercial application.Losses Narrowed Significantly, Making the Path to Profitability Increasingly ClearAlongside the rapid revenue growth, the Company's losses improved markedly. In the second half of 2025, the Company's net loss narrowed by 84% YoY, and its adjusted loss narrowed by 92% YoY, approaching break-even. This reflects the Company's ongoing improvements in cost control and operational efficiency.Simultaneously, some of the Company's operating metrics saw marked improvement. The adjusted expense ratio declined significantly by 10 percentage points YoY, while selling expenses decreased rather than increased and accounted for only 5.4%, highlighting a clear improvement in cost-to-efficiency ratio. In 2025, revenue per employee reached $365,300, up 25% YoY from $292,900 in 2024. Employee productivity continued to lead the industry, clearly underscoring the Company's core strengths in technology-driven, lean operations.Dual-Engine Strategy Gains Traction, with AI in Healthcare and AI in Daily Life Advancing in TandemIn 2025, driven by both technological breakthroughs and policy tailwinds, global demand for AI continued to rise. Unisound adhered to its "Strong Foundation Model + Deep Application" strategy, continued to strengthen its multimodal technology foundation, and drove the continuous elevation of the global influence of its proprietary large model matrix in fields such as healthcare, speech, and OCR.On the commercialization front, the Company leveraged its AI-native organization to accelerate business execution, and its dual-engine strategy in AI in Healthcare and AI in Daily Life delivered notable results. During the reporting period:The AI in Daily Life business achieved revenue of $140 million, a YoY increase of 30.8%. Among this, the Transportation segment recorded nearly 40% YoY growth. At present, AI agent applications based on the Shanhai large model have been deployed in more than 10 cities, including Qingdao, Ningbo, Shenzhen and Nanning. In addition, cumulative AI chip shipments exceeded 110 million units, further validating the Company's scale capabilities in endpoint AI products.The AI in Healthcare business achieved revenue of $35.38 million, a YoY increase of 22.3%, with average revenue per customer growing by 53.2% YoY. In 2025, over 70% of the hospitals the Company collaborated with were tertiary hospitals, and more than one-third of customers had maintained continuous cooperation for over three years. The medical-record entry and generation products powered by the medical large model delivered a 10-fold YoY increase in full-annual medical record generation at a single campus of a leading Class III hospital. The commercial insurance AI agent platform recorded a 37-fold YoY increase in case processing volume. In deep cooperation with a leading insurance group, the expense control rate was effectively raised to approximately 20%, delivering more than $145 million in incremental cost management compared with traditional review methods, comprehensively empowering insurance institutions to refine their medical risk management operations.Continued R&D Investment Strengthens the Technology MoatTo consolidate its industry-leading position, the Company continued to invest heavily in R&D in 2025. Full-year R&D expenses exceeded $55.09 million, accounting for 75% of the Company's adjusted operating expenses, while R&D personnel accounted for 69% of the total workforce. This sustained investment drove breakthroughs across multiple technology areas. For example, in the MedBench 4.0 evaluation, the Company ranked first place in three technical paradigms: "Medical AI Agent," "Medical Large Language Model," and "Medical Multimodal Large Model," earning a "Triple Crown."Outlook: Deepening the Technological Foundation and Expanding Application BoundariesLooking ahead, Unisound will continue to deepen its "Strong Foundation Model + Deep Application" strategy. On the technological front, the Company will continue to increase strategic investment in foundational large models and strive to maintain a world-class level. On the application front, it will use the large-scale expansion of MaaS (Model-as-a-Service) and AI agents as its core growth engine, driving exponential growth in its AI in Daily Life and AI in Healthcare businesses. Meanwhile, the Company is actively exploring the establishment of a recurring revenue system through models such as API calls and Token-based billing, and regards opportunities in consumer-facing (C-end) products as a second growth curve to further expand its commercialization boundaries.Between Q2 and Q3 2026, Unisound will launch a native AI agent large model for programming and office applications, which is expected to double both intelligence density and token production efficiency. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月26日，雲知聲（09678.HK）發佈截至2025年12月31日止年度的經審核全年業績，展現上市後首份成績單強勁的增長動能與持續優化的財務結構。營收結構持續優化，下半年增長提速2025年全年，雲知聲實現總營收12.1億元人民幣，同比增長29%。其中，下半年收入同比增長33%，達8.1億元。值得關注的是，公司大模型業務全年收入6.1億元，同比增長超10倍。尤其是下半年，該業務貢獻收入約5億元，為上半年規模的5倍，顯示出強勁的規模化落地能力。虧損大幅收窄，盈利路徑日漸清晰在營收高速增長的同時，公司虧損狀況顯著改善。2025年下半年，公司淨虧損同比收窄84%，經調整後虧損同比收窄92%，接近盈虧平衡點，反映出公司在成本控制與運營效率方面的持續優化。同時，公司的部分經營指標也得到明顯改善。經調整營業費用率較去年同比大幅下降10%，銷售費用不升反降，佔收入比重僅為5.4%，費效比提升明顯。從數據端來看，2025年公司人均產值為252萬元/人，相較24年的202萬元同比增長25%，人均創效能力持續領跑行業，直觀彰顯了公司技術驅動、精益運營的核心優勢。雙輪驅動戰略落地，智慧醫療與智慧生活齊頭並進2025年，在技術突破與政策紅利的雙重驅動下，全球人工智能市場需求持續升溫。雲知聲堅持「強基模+深應用」戰略，持續夯實全模态技術底座，推動自研大模型矩陣在醫療、語音、OCR等領域的全球影響力不斷提升。在商業化層面，公司以AI原生組織推動業務落地，智慧醫療與智慧生活雙輪驅動戰略成效顯著。報告期內：智慧生活業務實現收入9.68億元，同比增長30.8%。其中，智慧交通業務同比增長近40%，目前，已在青島、寧波、深圳、南寧等10餘個城市落地基於山海大模型的智能體應用。此外，AI芯片累計出貨量突破1.1億顆，進一步驗證公司在終端AI產品的規模化能力。智慧醫療業務實現收入2.44億元，同比增長22.3%，客單價同比增長53.2%。2025年，合作的醫院中超70%為三級醫院，且超過三分之一客戶已經連續合作三年以上；而基於醫療大模型的病歷錄入與生成產品已在某頭部三甲醫院單院區實現全年病歷生成同比增長10倍；商業保險智能體平台案件處理量同比增長37倍；與頭部保險集團的深度合作中，控費率水平有效提升至約20%，相較傳統審核方式實現超10億元級別的增量成本管控，全面賦能保險機構在醫療風控領域的精細化運營。持續加碼研發，夯實技術護城河為鞏固行業領先地位，2025年公司持續在技術端大力投入，全年研發費用超3.8億元，佔經調整三費的75%；研發人員佔比達69%。持續的研發投入在多個技術領域取得突破，如在MedBench 4.0評測中，公司一舉斬獲「醫療智能體」「醫療大語言模型」「醫療多模态大模型」三項技術範式第一，榮膺「三冠王」。未來展望：深耕技術底座，拓展應用邊界展望未來，雲知聲將繼續深化「強基模+深應用」戰略。技術層面，公司將持續加大對基座大模型的戰略性投入，力爭保持全球一流水平；應用層面，將以MaaS（模型即服務）與智能體的規模化拓展為核心增長引擎，推動智慧生活與智慧醫療業務的指數級增長。同時，公司正積極探索以API調用、Token計費等模式構建經常性收入體系，並將C端產品機會作為第二增長曲線，進一步拓展商業化邊界。2026年第二季度，雲知聲將推出面向編程和辦公的原生智能體大模型，並預計能實現智能密度和Token生產效率的倍增。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 2026年3月26日，心瑋醫療（06609.HK）公佈了2025年業績公告。2025度，公司收入4.08億元，同比增長46.9%，淨利潤8334萬元，較上年度虧損約1362萬元實現重大扭虧為盈。這一轉變主要由於公司在缺血性卒中、出血性卒中及介入通路三大業務板塊均實現了收入的快速增長，同時公司的經營效率進一步提升。2025年，公司的缺血性卒中業務收入同比增長31.8%，主要由於：(1)公司具有差異化競爭優勢的顱內血栓抽吸導管得到臨床的廣泛認可，大腔抽吸及級聯抽吸技術(CATCH)被納入《急性缺血性卒中血管內治療技術中國專家共識2025》，產品進入超過450家醫院使用，收入規模快速提升；(2)成熟產品在納入集采後，銷量快速增長。在出血性腦卒業務中，公司已構建完整動脈瘤治療解決方案。公司的顱內支架（獲NMPA創新醫療器械認定）在首個商業化年度累計進入約500家醫院使用，帶動栓塞彈簧圈的市場份額快速提升。同時，公司的血流導向裝置於2025年獲NMPA批准上市，實現臨床推廣和應用。基於前述原因，公司的出血性卒中業務收入在2025年同比增長223.2%。在介入通路業務中，公司的明星產品血管封堵器累計進入超過1800家醫院使用，年終端醫院臨床使用量超過20萬條，在2025年實現單產品收入過億。與此同時，公司正推動第二代血管封堵器的開發和商業化，以繼續擴大市場份額。公司的毛利率從2024年度的65.4%提升至2025年的70.9%，主要由於高毛利創新產品的收入占比提升，以及公司持續推動的生產工藝改進、供應鏈優化等降本措施的有效實施。不斷完善的產品佈局以及持續的降本增效工作，使公司在面臨激烈的市場競爭情況下，仍能保持優質的產品品質及突出盈利能力。公司在業務規模擴大的同時，費用控制效果顯著，銷售及管理費用率較2024年相比從49.6%降至45.8%。報告期內，公司發生研發費用人民幣4076萬元，主要用於神經介入醫療器械及腦機介面等創新產品的開發。截至目前，公司已取得以下各項進展：(1)在缺血性卒中領域，公司已取得顱內血栓抽吸導管、取栓支架及配套通路產品的註冊證。公司的自膨式顱內藥物洗脫支架已完成對照臨床試驗，註冊申請已獲NMPA受理。根據公開信息查詢結果，目前全球未有類似產品獲批上市，公司在此類產品的研發進度上領先業界。在頸動脈狹窄領域，公司正推動開展頸動脈支架的臨床試驗工作；(2)在出血性卒中領域，公司是獲證最全面的國產公司，實現顱內支架（獲NMPA創新醫療器械認定）、血流導向裝置、栓塞彈簧圈、神經血管封堵球囊導管的完整佈局；(3)同時，公司正積極推進創新產品介入式腦機接口的研發工作。該產品在有效提取大腦信號以用於完成人機交互的同時，保障了手術的安全性和產品長期植入的穩定性，有望在2026年開展首例人體臨床試驗。2025年，公司的海外市場收入較2024年增長101.3%，這主要歸功於公司快速推進的海外產品註冊工作及產品推廣工作。海外市場方面，公司的取栓支架、封堵球囊導管、遠端通路導管以及微導管已取得CE或FDA認證，並在其他13個國家或地區取得56項註冊證書。截至目前，公司還在其他29個國家或地區開展超過130個產品註冊工作，擴展銷售管道，為實現海外銷售的長期目標建立基礎。2025年，公司經營性現金流1.55億元，帳面現金及存款7.86億元，整體資金狀況穩健。依託扎實的財務實力，公司已於2025年完成股份回購3936萬港元，並將持續推進股份回購工作，積極維護全體股東利益。此外，公司計劃於2026年提交A股科創板上市申請，借助登陸境內資本市場進一步提升股東回報水平與股份市場流動性。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 2026年3月26日，北京城建設計發展集團股份有限公司（"本公司"或"公司"，簡稱"城建設計"，股票代碼：1599.HK）董事會（"董事會"）欣然公佈本公司及其子公司（合稱"本集團"）截至2025年12月31日止年度（"2025年度"或"報告期"）的經審計業績。2025年，公司面對市場持續下行壓力，緊緊圍繞高質量發展，迎難而上、實幹擔當，聚焦主責主業，推動全產業鏈協同發力，階段性完成了"十四五"規劃主要目標任務，為新征程加快發展積蓄了強勁動能。截至2025年12月31日止年度，本集團實現收入為人民幣75.27億元。本集團實現淨利潤為人民幣5.36億元，同比上漲1.52%。綜合毛利率19.85%，同比上漲1.77%。核心主業與新興領域協同發力，高端諮詢品牌效應顯現設計、勘察及諮詢板塊為本集團的傳統和主營核心業務，報告期內，本集團軌道交通領域中標成都27號線二期、廈漳泉城際鐵路（廈門段）等重點項目；既有線改造市場成效顯著，中標北京、南京、哈爾濱、長春、瀋陽等一批代表性項目，市場份額保持領先；高端諮詢品牌效應持續顯現，成功承擔了香港鐵路標準、北京三期線網技術標準等標杆項目，專業服務能力穩步提升；境外業務紮實推進，在香港、新加坡、安哥拉、哈薩克斯坦、哥倫比亞持續獲取訂 單，新簽合同額突破人民幣1億元；民建、市政設計走特色化發展之路，在居住建築、大型TOD、校園、道路等傳統領域精耕細作，積極向展陳、城市更新、水環境治理領域延伸佈局。截至2025年12月31日止年度，本集團設計、勘察及諮詢板塊業務收入人民幣40.89億元。其中城市軌道交通工程板塊收入人民幣29.38億元，工業與民用建築和市政工程板塊收入人民幣11.51億元。本集團工程承包業務板塊專注於服務城市軌道交通建設項目和相關基礎設施建設項目，2025年，本集團中標北京軌道交通R4線一期北段01標、03標、M101線05標、市郊鐵路東北環線03標等項目，進一步鞏固了北京核心市場，在手工程承包項目主要集中在北京、廣州、重慶、烏魯木齊及青島等城市。截至2025年12月31日止年度，本集團工程承包業務板塊實現收入人民幣34.38億元。新建項目與存量改造雙線發力，中標額突破81億元，在手訂單儲備充足2025年，軌道交通行業面臨市場持續下行、招標規模顯著縮減、行業競爭加劇及宏觀經濟形勢不確定性增強的局面，公司始終全力以赴力爭中標軌道交通新建項目，尤其注重穩固北京區域市場份額。在守住基本盤的同時，積極佈局既有線改造、城市更新、能源、數字化及智慧等其他高潛力板塊，以應對市場變化並提升抗風險能力。截至2025年12月31日，公司中標金額人民幣81.71億元，其中設計、勘察及諮詢業務板塊中標人民幣26.39億元，工程總承包板塊中標人民幣55.32億元。報告期末公司在手合同額為人民幣251.43億元。2026年展望：錨定"十五五"開局，推動高質量發展2026年是"十五五"開局之年，面對深刻變化的市場形勢和艱巨繁重的發展任務，我們要積極把握戰略機遇，主動適應行業發展新格局，以穩中求進為總基調，以推動高質量發展為主題，以改革創新為根本動力，錨定打造"以設計為引領的城市建設綜合服務商"戰略目標，確保"十五五"開好局、起好步。有關城建設計北京城建設計發展集團股份有限公司（股份代碼：1599.HK）是國內第一家以城市軌道交通設計諮詢為引領的H股上市企業。公司前身是北京城建設計研究總院成立於1958年，是為中國首條地鐵北京地鐵1號線的勘察設計而成立。擁有國內設計勘察行業最高資質—綜合甲級資質。作為行業龍頭和市場規範的制定者，公司由成立至今仍保持市場佔有率第一的位置。基本業務涵蓋投融資、勘察設計諮詢、工程總承包、科技產業化、運營管理的城市軌道交通全產業鏈。公司市場覆蓋了全國已批復軌道交通建設規劃城市的80%，業務拓展到了國內近70個城市，在50多個城市擁有分支機構。新聞垂詢：千里國際顧問有限公司fancywang@maxima.hk Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

財務摘要人民幣（億元）截至12月31日止12個月變動2025年2024年營業收入1566.111,776.64-11.85%營業利潤28.4265.53-56.64%稅前利潤28.1665.95-57.30%毛利194.95222.47-12.37%毛利率12.45%12.52%-0.07pct淨利潤13.3741.95-68.12%歸屬于母公司股東及其他權益持有者的淨利潤2.2129.72-92.57%經營活動產生的現金流量淨額185.1492.6499.86%每股派息（元/股，含稅）0.1790.176N/A派發現金紅利（含稅）9.399.45-0.60%業績亮點1.經營底盤穩健，高品質發展韌性凸顯：2025年集團實現營業收入人民幣1566.11億元，淨利潤人民幣13.37億元，毛利率維持12.45%，海內外營收結構均衡。2.現金流與財務品質雙改善，抗風險能力顯著增強：經營活動現金流淨額大幅增長99.86%至185.14億元，期末貨幣資金餘額243億元；有息債務規模同比縮減47億元至人民幣344億元、淨利息費用同比下降約7.3億元，財務結構持續優化。3.現金分紅+回購雙管齊下，全力回報投資者：2025年擬每股派現金人民幣0.179元(含稅)，疊加年內推出的H股、A股多輪回購計畫，2025年度公司擬分紅及已回購金額合計達到人民幣18.52億元。4.能源相關業務盈利能力大幅躍升，成為集團重要增長極：海洋工程分部、金融資產管理分部(主要為鑽井租賃)淨利潤合計增長約12.12億，能源化工及液態食品分部增長3.08億。其中，海洋工程分部毛利率大幅提升5.72個百分點至14.83%。海洋工程、能源化工及液態食品在手訂單分別達50.9億美金及297.5億人民幣，部分船廠排產至2030年。5.物流相關業務穩固集團"壓艙石"作用：期內，集裝箱、道路運輸車輛等業務受匯率及週期波動影響，毛利率及盈利有所承壓，但基本盤穩健，行業競爭優勢持續鞏固，集裝箱標準幹箱、冷藏箱、化工罐箱、半掛車等核心產品連續多年保持全球第一。6.關鍵業務取得技術與訂單雙突破，競爭力獲高度認可：高端海工裝備領域，中集來福士攻克海工行業最複雜產品FPSO/FLNG，成為中國唯一一家擁有雙專案EPCI總包能力的企業；模組化資料中心領域，同時為超過300MW的行業客戶提供預製化資料中心的技術與製造交付服務，引領算力基礎設施新變革。香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 中國國際海運集裝箱（集團）股份有限公司（簡稱"中集集團"或"集團"，股份代號：000039.SZ/02039.HK）欣然公佈截至2025年12月31日止12個月（"期內"）之經審核全年業績。中集集團管理層表示，2025年，全球百年變局加速演進，世界經濟在波折中展現韌性。置身于機遇與挑戰並存的時代洪流，集團緊緊圍繞"構建增長新動能、聚力高品質發展"主基調，不僅穩住經營基本盤，更以前瞻性戰略深化能源業務佈局，取得豐碩成果。2025年全年，集團實現營業收入人民幣1566.1億元，淨利潤達人民幣13.4億，公司經營活動產生的現金流量淨額大幅增長99.9%至185.1億元，資產結構持續優化，抗風險能力持續增強。特別地，為真情回饋廣大投資者，中集集團2025年擬向全體股東每1股份派現金股利人民幣0.179元（含稅），此次合計擬派發現金紅利人民幣9.39億元（含稅）；同時，中集集團於2025年度已實施的股份回購金額累計達9.13億人民幣，兩者合計總額達到18.52億元。主要板塊經營表現（人民幣億元）2025各項指標營業收入占總營收比重毛利占總毛利比重毛利率淨利潤集裝箱製造430.0927.46%57.5529.52%13.38%18.82道路運輸車輛201.7812.88%32.0616.45%15.89%9.27能源、化工液態食品裝備271.9217.36%40.2420.64%14.80%10.40海洋工程179.3811.45%26.6013.65%14.83%10.57物流服務 267.9317.11%16.708.57%6.23%3.64空港與物流裝備、消防與救援設備76.194.86%15.147.76%19.87%2.64以上主要板塊1427.2991.12%188.2996.59%13.19%55.34核心業務表現一、在物流領域集裝箱製造方面: 期內，雖受美國關稅政策擾動與地緣政治衝突等供應鏈負面因素影響，全球商品貿易仍展現出較強韌性，區域內貿易、亞歐及新興市場航線成為增量主力。與此同時，紅海繞行、港口擁堵、航運環保要求及貿易路徑複雜化等因素，降低了集運效率，從底層推升實際需求，全球集裝箱保有量進入新的結構性階段。綜上，2025年集裝箱新箱整體需求仍保持較好水準，高於過去十年均值。報告期內，集團集裝箱製造業務產銷量同比有所回落，符合行業整體預期，但仍舊保持全球第一。其中乾貨集裝箱累計銷量222.49萬TEU（去年同期：343.36萬TEU），同比下降35.2%；冷藏箱累計銷量20.82萬TEU（去年同期：13.86萬TEU），同比增長50.2%。期內，集裝箱板塊實現營業收入430.09億元，淨利潤18.82億元，毛利率略有下降至13.38%。物流服務業務方面: 期內，該業務實現營業收入人民幣267.93億元，同比下降14.64%；淨利潤為人民幣3.64億元，同比下降16.65%，符合行業趨勢變化。中集世聯達主動調整業務架構，整合業務資源，期內海運業務自攬貨量同比增長6%，港口物流業務的二手箱交易、倉儲分撥創歷史新高，行業物流業務聚焦新能源、汽車、工程項目等重點領域鞏固細分優勢。2025年，中集世聯達在中國國際貨運代理協會發佈的"貨代物流企業綜合榜"中連續3年位列前五。道路運輸車輛方面: 期內，中集車輛實現收入人民幣201.78億元，同比下降3.91%；實現淨利潤人民幣9.27億元，同比下降14.29%。國內市場方面，"星鏈計畫"重塑組織運營模式，中國半掛車業務營業收入同比增長14.65%，毛利率同比提升3.3%。海外市場方面，全球南方市場業務延續高品質增長，期內營收規模達30.9億元，同比增長17.7%，銷量同比大幅提升29.1%，毛利率同比提升1.3個百分點。DTB業務銷量和營收穩健增長,上裝產品總計28,570台，整體收入達人民幣31.84億元，同比增長4.97%，核心產品市場佔有率進一步提升。同時，持續積極擴展新能源產品的研與銷力度，全面構建EV-RT生態圈，深度推進純電動頭掛列車的戰略發展。空港與物流裝備、消防與救援設備方面: 得益於優質訂單釋放結轉，期內實現營業收入人民幣76.19億元，同比增長5.92%；實現淨利潤人民幣2.64億元。空港裝備成功交付西安咸陽國際機場、土耳其安塔利亞機場及蘭州機場等智慧登機橋專案，亦憑藉自主研發的創新裝配式固定橋，中標南寧機場二期、杭州機場T2/T4連廊兩大重點專案；物流裝備交付國內化工行業石化煉化專案一體化項目配套自動化立體倉庫；消防與救援設備業務推動國產製造海外突圍，同時重點佈局智慧消防與無人消防車前沿領域。二、在能源領域能源、化工及液態食品裝備業務方面，實現營業收入人民幣271.92億元，同比上升6.31%；淨利潤大幅增長42.15%至人民幣10.40億元。其中，中集安瑞科實現營業收入人民幣263.26億元，同比增長6.3%。具體來看，清潔能源分部水上與陸上業務同步發力，在高壓、低溫等關鍵裝備的市場持續獲得領先份額，同時精准抓住天然氣在水陸交通、發電等領域的應用增長機遇，同時積極開拓特種工業氣體設備在高新科技產業的新興增長空間。2025年，該分部新簽訂單達222.29億元，創歷史新高，其中水上清潔能源相關業務截至2025年底在手訂單超人民幣190億元，造船業務已排產至2028年。報告期內成功投產第二個焦爐氣綜合利用項目——淩鋼一期項目、建成國內首個量產生物甲醇項目並實現投產；化工環境分部市場份額穩居首位，醫療設備部件業務、後市場服務業務保持穩健增長。截至2025年年末的在手訂單同比增長36.27%至12.76億元，為後期發展提供較好保障；液態食品分部盈利能力穩健，毛利率較同期提升至21.7%。海洋工程方面，主要經營主體中集來福士成功實現從"建造主導"向"設計+建造+集成"一體化服務的戰略轉型，國內市場穩居領先，躋身國際海工市場重要新生力量。報告期內實現營業收入人民幣179.38億元，同比增長8.35%；淨盈利人民幣10.57億元，成集團第二大盈利板塊。得益於全球海工市場復蘇，以FPSO/FLNG為代表的高端油氣裝備需求強勁，同時全行業正加速向綠色化與智慧化轉型，新能源裝備訂單保持穩定增長。年內，公司新簽合同訂單12.0億美元，包括12+8條集裝箱支線船、2條海工特種船及其它模組訂單。截止2025年底，海洋工程板塊累計持有在手訂單價值50.9億美元，其中油氣、特種船訂單占比約為7:3，其中龍口基地已排產至2030年。海工資產運營管理業務方面，公司持續發揮現有專案經驗和業務能力，借助優異的海工平臺運營管理能力，提高資產上租率。報告期內，第六代半潛鑽井平臺"仙境煙臺"完成續租簽約；超深水半潛鑽井平臺"藍鯨一號"與國際客戶簽署新租約；半潛式起重/生活平臺"Blue Gretha（原華電中集01）"與國際客戶簽署新租約；其他多座平臺也在通過多種管道積極參與市場招標，尋求資產處置及租賃等業務機會。報告期內，上租半潛鑽井平臺及自升式鑽井平臺的平均日費率均實現同比增長。未來發展和展望集團管理層表示："2026年是‘十五五’規劃開局之年，集團將以全新升級的品牌標誌為起點，緊緊圍繞‘固本強基、開拓創新、提質增效’，以更加積極主動的戰略姿態，在複雜變局中育新機、開新局，努力建設‘高品質的、受人尊敬的世界一流企業’。"關於中國國際海運集裝箱（集團）股份有限公司中集集團是全球領先的物流及能源行業設備及解決方案供應商，產業集群主要涵蓋物流領域及能源行業領域，龍頭市場地位持續鞏固。在物流領域，本集團仍然堅持以集裝箱製造業務為核心，孵化出道路運輸車輛業務、空港與物流裝備/消防與救援設備業務，輔之以物流服務業務及迴圈載具業務提供物流專業領域的產品及服務；在能源行業領域，本集團主要從能源/化工/液態食品裝備業務、海洋工程業務方面開展；同時，本集團也在不斷開發新興產業並擁有服務本集團自身的金融及資產管理業務。作為一家為全球市場服務的多元化跨國產業集團，中集在亞洲、北美、歐洲、澳洲等地區擁有300余家成員企業，共擁有4家上市公司，客戶和銷售網路分佈在全球100多個國家和地區。2025年，本集團業績實現營業收入人民幣1566億元，位列2025《財富》中國500強榜單第154名。在集裝箱標準幹箱、冷藏箱、化工罐箱、半掛車等核心產品領域連續多年保持全球第一。如欲獲得更多資訊，請流覽https://www.cimc.com/。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial HighlightsRMB 100 millionFor the 12 months ended 31 DecemberChange (%)20252024Revenue1566.111,776.64-11.85% Profit28.4265.53-56.64% Profit before Tax28.1665.95-57.30% Gross Profit194.95222.47-12.37% Gross Profit Margin12.45%12.52%-0.07pct Net Profit13.3741.95-68.12% Net Profit Attributable to Shareholders and Other Equity Holders2.2129.72-92.57% Net cash flows from operating activities 185.1492.6499.86% Dividend per share (RMB/share, tax inclusive)RMB 0.179RMB 0.176N/A Total dividend payout9.399.45-0.60% Performance Highlights1. Solid operating core segments with resilient high-quality development: In 2025, the Group achieved revenue of RMB 156.611 billion, net profit of RMB 1.337 billion, and maintained a gross profit margin of 12.45%, with a balanced domestic and overseas revenue structure.2. Dual improvement in cash flow and financial quality, with significantly enhanced risk resilience: Net cash flows from operating activities increased substantially by 99.86% to RMB 18.514 billion, while the cash and cash equivalents as of the end of the Year reached RMB 24.3 billion; the scale of interest-bearing debt decreased by RMB 4.7 billion year-on-year (“YoY”) to RMB 34.4 billion, and net interest expenses decreased by approximately RMB 730 million YoY, with the financial structure continuing to be optimized.3. Cash dividends and share buybacks implemented in parallel to reward investors: The Group proposes a cash dividend of RMB 0.179 per share (tax inclusive) for 2025. Together with multiple rounds of H-share and A-share buyback plans launched during the Year, the total proposed dividend and completed buybacks for 2025 amounted to RMB 1.852 billion.4. Significant improvement in profitability of energy-related businesses, becoming a key growth driver of the Group: Net profit of the offshore engineering segment and the financial and asset management segment (primarily drilling platform leasing) increased by approximately RMB 1.212 billion in total, while the energy, chemical and liquid food equipment segment increased by RMB 308 million. Among them, the gross profit margin of the offshore engineering segment increased significantly by 5.72 percentage points to 14.83%. Orders on hand for offshore engineering and energy, chemical and liquid food equipment reached US$5.09 billion and RMB 29.75 billion, respectively, with certain shipyards’ production schedules extending to 2030.5. Logistics-related businesses continued to serve as the Group’s “ballast stone”: During the Year, businesses such as container manufacturing and road transportation vehicles were affected by exchange rate fluctuations and cyclical changes, resulting in pressure on gross profit margins and profitability. However, the core segments remained solid, and the Group’s competitive advantages in the industry continued to be consolidated. Core products such as standard dry containers, reefer containers, tank containers and semi-trailers have maintained the world’s No.1 position for many consecutive years.6. Breakthroughs in both technology and orders in key businesses, with competitiveness highly recognised: In the high-end offshore engineering equipment sector, CIMC Raffles successfully developed the most complex products in the offshore industry, including FPSO/FLNG, becoming the only enterprise in China with dual-project EPCI general contracting capabilities; in the modular data center sector, the Group providing technical and manufacturing delivery services of prefabrication data center to industry customers exceeding 300MW, leading new transformation in computing power infrastructure.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – China International Marine Containers (Group) Co., Ltd. (“CIMC Group” or the “Group”, stock code: 000039.SZ/02039.HK) is pleased to announce the audited annual results for the 12 months ended 31 December 2025 (the “Year”).The Group’s management stated, “In 2025, profound global changes unseen in a century accelerated, and the global economy demonstrated resilience amid volatility. Positioned in an era of both opportunities and challenges, the Group closely adhered to the strategic theme of “accelerating the construction of new growth drivers and focusing on promoting high-quality development”. While stabilising its operating fundamentals, the Group further deepened its forward-looking strategic layout in the energy business and achieved fruitful results. For the year of 2025, the Group recorded revenue of RMB 156.61 billion and net profit of RMB 1.34 billion. Cash flows from operating activities increased significantly by 99.9% to RMB 18.51 billion, with the asset structure continuously optimized and risk resilience further enhanced.”In particular, to sincerely reward investors, CIMC Group proposes to distribute a cash dividend of RMB 0.179 per share (tax inclusive) to all shareholders for 2025, amounting to a total proposed cash dividend of RMB 939 million (tax inclusive). Meanwhile, the Group implemented share buybacks totalling RMB 913 million during 2025, bringing the combined total to RMB 1.852 billion.Segments Results (RMB 100 million)2025 Business indicatorsRevenueAs % of the total revenueGross profitAs % of the gross profitGross profit marginNet profitContainer manufacturing430.0927.46%57.5529.52%13.38%18.82Road transportationvehicles201.7812.88%32.0616.45%15.89%9.27Energy, chemical, and liquid food equipment271.9217.36%40.2420.64%14.80%10.40Offshore engineering179.3811.45%26.6013.65%14.83%10.57Logistics services267.9317.11%16.708.57%6.23%3.64Airport facilities and logistics equipment/fire safety and rescue equipment76.194.86%15.147.76%19.87%2.64Total of major segments1427.2991.12%188.2996.59%13.19%55.34Core Business Performance1. In logistics field:In the container manufacturing business, during the Year, despite negative supply chain factors such as U.S. tariff policies and geopolitical conflicts, global merchandise trade demonstrated strong resilience. Intra-regional trade, Asia-Europe routes and emerging market routes became the main drivers of incremental growth. Meanwhile, factors such as detours around the Red Sea, port congestion, environmental requirements in shipping and increasing complexity of trade routes reduced transportation efficiency, structurally boosting underlying demand and pushing the global container fleet into a new structural phase. As a result, overall demand for new containers in 2025 remained at a relatively high level, exceeding the average of the past decade. During the Year, the production and sales volume of the Group’s container manufacturing business declined YoY, in line with overall industry expectations, but the Group maintained its global No.1 position. Accumulated sales volume of dry cargo containers reached 2,224,900 TEUs (2024: 3,433,600 TEUs), representing a YoY decrease of 35.2%. Accumulated sales volume of reefer containers reached 208,200 TEUs (same period last year: 138,600 TEUs), representing a YoY increase of 50.2%. During the Year, the container manufacturing segment recorded revenue of RMB 43.009 billion, net profit of RMB 1.882 billion, and a slight decline in gross profit margin to 13.38%.In the logistics services business, during the Year, the segment recorded revenue of RMB 26.793 billion, representing a YoY decrease of 14.64%, and net profit of RMB 364 million, representing a YoY decrease of 16.65%, in line with industry trends. CIMC Wetrans actively adjusted its business structure and integrated resources. During the Year, self-sourced cargo volume increased by 6% YoY, while second-hand container trading and warehousing distribution in port logistics reached record highs. The industry logistics business focused on key sectors such as new energy, automotive and engineering projects to consolidate its niche advantages. In 2025, CIMC Wetrans ranked among the top five for three consecutive years in the “Comprehensive List of Freight Forwarding and Logistics Enterprises” published by the China International Logistics and Freight Forwarding Association.In the road transport vehicles business, during the Year, CIMC Vehicles recorded revenue of RMB 20.178 billion, representing a YoY decrease of 3.91%, and net profit of RMB 927 million, representing a YoY decrease of 14.29%. In the domestic market, the “Star-Chained Plan” reshaped the organisational and operational model, with revenue from the China semi-trailer business increasing by 14.65% YoY and gross profit margin increasing by 3.3%YoY. In overseas markets, the Global South markets maintained high-quality growth, with revenue reaching RMB 3.09 billion during the Reporting Period, representing a YoY increase of 17.7%, sales volume increasing by 29.1% YoY, and gross profit margin increasing by 1.3 percentage points YoY.The DTB business achieved steady growth in both sales volume and revenue, with a total of 28,570 units of mounted equipment products delivered, generating total revenue of RMB 3.184 billion, representing a YoY increase of 4.97%, with further improvement in market share of core products. Meanwhile, the Group continued to actively expand R&D and sales of new energy products, comprehensively building the EV-RT ecosystem and advancing the strategic development of pure electric tractors and trailers.In the airport facilities and logistics equipment/fire safety and rescue equipment, benefiting from the release and delivery of high-quality orders, the segment recorded revenue of RMB 7.619 billion during the Year, representing a YoY increase of 5.92%, and net profit of RMB 264 million. Airport equipment successfully delivered smart boarding bridges projects for Xi’an Xianyang International Airport, Antalya Airport in Türkiye and Lanzhou Airport, and secured major projects including Phase II of Nanning Airport and corridor projects at Hangzhou Airport T2 and T4 with its independently-developed innovative prefabricated fixed bridge solutions. Logistics equipment delivered automated three-dimensional warehouse systems for supporting the petrochemical and refining integration project in China. The fire safety and rescue equipment business advanced the overseas expansion of domestically manufactured products while focusing on frontier areas such as smart fire safety and unmanned fire trucks.2. In the Energy FieldIn the energy, chemical, and liquid food equipment business, the segment recorded revenue of RMB 27.192 billion, representing a YoY increase of 6.31%, and net profit increased significantly by 42.15% to RMB 1.040 billion. Among which, CIMC Enric recorded revenue of RMB 26.326 billion, representing a y YoY increase of 6.3%.Specifically, the clean energy segment advanced both offshore and onshore businesses, maintaining leading market share in key equipment such as high-pressure and cryogenic equipment, while capturing growth opportunities in natural gas applications in water and land transportation and power generation, and actively expanding into emerging markets for special industrial gas equipment in high-tech industries. In 2025, the segment secured new orders of RMB 22.229 billion, a record high. Among these, orders on hand for offshore clean energy-related business exceeded RMB 19 billion as of the end of 2025, with shipbuilding schedules extending to 2028. During the Year, the second coke oven gas comprehensive utilisation project — Linggang Phase I project — was successfully put into operation, and China’s first domestic mass-production bio-methanol (green methanol) project of CIMC Enric was completed and commenced operation. The chemical and environmental segment maintained its leading market share, while the medical equipment components and after-sales service businesses achieved steady growth. As of the end of 2025, orders on hand increased by 36.27% YoY to RMB 1.276 billion, providing strong support for future development. The liquid food segment maintained stable profitability, with gross profit margin increasing to 21.7% YoY.In the offshore engineering business, the Group’s core operating entity, CIMC Raffles, successfully achieved a strategic transformation from “manufacturing-led” to integrated “design + construction + integration” services, maintaining a leading position in the domestic market and emerging as an important new force in the international offshore engineering market. During the Reporting Period, the segment recorded revenue of RMB 17.938 billion, representing a YoY increase of 8.35%, and net profit of RMB 1.057 billion, becoming the Group’s second-largest profit contributor. Benefiting from the recovery of the global offshore engineering market, demand for high-end oil and gas equipment represented by FPSO/FLNG remained strong, while the industry accelerated its transition toward green and intelligent development, driving steady growth in new energy equipment orders. During the year, the Group secured new contract orders of US$1.20 billion, including 12+8 container feeder vessels, 2 offshore engineering special vessels and other module orders. As of the end of 2025, the accumulated value of orders on hand reached US$5.09 billion, with orders for oil & gas and special vessel accounting for approximately 70% and 30%, respectively. The Longkou base has scheduled production through to 2030.In the offshore engineering asset operation and management business, the Group continued to leverage its existing project experience and business capabilities, enhancing asset utilisation through its strong offshore platform operation and management capabilities. During the Reporting Period, the sixth-generation semi-submersible drilling platform “Deepsea Yantai” completed lease renewal, the ultra-deepwater semi-submersible drilling platform “Blue Whale No.1” signed a new lease with an international client, and the semi-submersible lifting/life platform “Blue Gretha (formerly Huadian CIMC 01)” also secured a new lease with an international client. Other platforms actively participated in market tenders to explore opportunities for asset disposal and leasing. During the Reporting Period, the average daily lease rate of semi-submersible and jack-up drilling platforms both recorded year-on-year increases.Future Development and ProspectsThe Group’s management stated, “The year 2026 marks the beginning of the ‘15th Five-Year Plan’. Starting from a newly upgraded brand identity, the Group will closely focus on ‘consolidating foundations, driving innovation, improving quality and efficiency’, and adopt a more proactive strategic approach to foster new opportunities and open new horizons amid complex changes, striving to build a ‘“becoming a high quality and trustworthy world-class multimodal transport enterprise.”About China International Marine Containers (Group) Co., Ltd.The CIMC Group is a world-leading equipment and solution provider in the logistics and energy industries, with its industry clusters mainly covering the logistics and energy fields, continuously strengthening its leading market position. In the logistics field, the Group continues to adhere to container manufacturing as its core business, based on which it has incubated the road transportation vehicles business and the airport facilities and logistics equipment / fire safety and rescue equipment business, supplemented by the logistics services business and recycled load business, providing products and services in the professional logistics field. In the energy field, the Group is principally engaged in the energy, chemical and liquid food equipment business and the offshore engineering business. Meanwhile, the Group continues to develop emerging industries and possesses financial and asset management businesses that serve the Group itself. As a diversified multinational industrial group serving the global market, CIMC has over 300 member enterprises across Asia, North America, Europe, and Australia, with a total of four listed companies, and customers and sales networks covering more than 100 countries and regions worldwide. In 2025, the Group recorded revenue of RMB 156.6 billion, ranking 154th on the 2025 Fortune 500 China list. The Group has maintained the world’s No.1 position for many consecutive years in core products such as standard dry containers, reefer containers, tank containers and semi-trailers. For more information, please visit http://www.cimc.com/. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 3月26日，中國生物製藥有限公司公佈 2025 全年業績。年內實現營業收入318.3 億元（人民幣，下同），按年增長 10.3%；經調整Non-HKFRS歸母淨利潤45.4 億元，按年增長 31.4%，連續四個財報期維持雙位數增長，整體表現明顯優於行業平均水平。集團最核心亮點在於創新產品商業化持續放量。2025 年創新產品收入達152.2 億元，按年大增 26.2%，規模處於行業前列，高增速反映創新轉型成效顯著，亦為業績提供可持續支撐。2023‑2025 年三年間，集團累計獲批創新產品 16 款，其中國藥 1 類創新藥達 7 款，成果轉化效率領先行業，成為帶動業績增長的關鍵動力。年內集團再添 4 款創新藥獲國家藥監局（NMPA）批准上市，包括針對 HER2 肺癌、CDK2/4/6 抑制劑、重組七因子及獲 FDA 批準的鎮痛新藥等具突破性產品。核心品種安羅替尼再增 3 項一線適應症，總數擴至 10 項，進一步鞏固抗血管生成藥物領先地位。在腫瘤、肝病 / 心血管代謝、呼吸 / 自免、外科 / 鎮痛四大核心領域，公司已建立完整產品矩陣，支撐長期穩健增長。董事會主席謝其潤表示，連續四期雙位數增長驗證集團在創新研發、BD 合作及併購整合的長期佈局成效。2026 年是集團全面國際化的新起點，年初重磅對外授權項目成為重要里程碑，為創新管線打開全球估值空間。研發方面，集團維持高強度投入，2025 年研發開支達58.7 億元，按年增長逾 15%，佔收入比重 18.4%，雙雙創歷史新高。目前已搭建小分子、ADC、siRNA、蛋白降解劑等多個核心技術平台，於上海、北京、廣州等地設立研發中心，研發團隊超 2900 人，推進臨床項目超 130 個。透過 AI 技術賦能研發全流程，PCC 發現時間提速超 50%，臨床篩選週期縮短約 30%，研發質效顯著提升。首席執行長謝承潤指出，集團在鞏固本土優勢之餘，堅定推進國際化與數碼化戰略，多項重磅創新資產已具備全球競爭力。2026 年開局表現強勢：1 月以 12 億元收購 siRNA 技術平台赫吉亞；2 月 FIC 新藥羅伐昔替尼獲批，並將全球權益授權予賽諾菲，交易潛在總金額超 15 億美元，開啟國際化第二增長曲線。展望未來三年（2026‑2028），集團創新管線將進入密集收穫期，預計逾 20 款創新藥或新適應症有望上市，涵蓋多個 FIC/BIC 潛力品種。於腫瘤、呼吸、肝病代謝、外科鎮痛領域均有重磅品種推進，包括 CLDN18.2 ADC、雙抗、PDE3/4 抑制劑、pan‑PPAR 激動劑等，管線梯次清晰、儲備充足。整體而言，中國生物製藥已由仿製驅動成功轉向創新驅動，憑藉高研發投入、高效商業化與國際化佈局，進入高質量增長階段。隨著創新產品持續放量、管線逐步兌現，集團長期增長動能充足，在港股藥板塊中具備突出配置價值。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial Highlights (Audited)(HKD Thousand)Year ended31 December20252024Revenue170,011271,372Gross Profit53,382104,720Profit Attributable to Owners of the Company13,68833,440Basic Earnings per Share (HK cents)0.972.37HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Dynasty Fine Wines Group Limited (“Dynasty” or “the Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2025 (“the Year”).In 2025, due to the impact of macroeconomy as well as weak demand in wine consumer market in the PRC, the Group’s sales of medium to high-end products significantly declined, resulting in a 37% year-on-year decrease in revenue to HK$170.0 million. In addition, due to the decline in sales revenue and gross margin, as well as an increase in loss allowances for trade receivables owing to extended repayment from certain distributors, the profit attributable to owners of the Company decreased by 59% year-on-year to approximately HK$13.7 million, although such decrease in profit was already partly offset by a net gain on compensatory surrender recognised during the year. Earnings per share of the Company was HK0.97 cents per Share.With strengthened marketing effort for dry white in coastal region and the launch of new white wine and sparkling wine products, sales of white wine products served as the Group’s primary revenue contributor. Sales of red and white wines products accounted for approximately 39% and 54% of the revenue respectively for the year (2024: approximately 41% and 56% respectively). The gross margin of red wine products and white wine products in 2025 were 25% and 35% respectively (2024: 36% and 41% respectively). The overall gross profit margin decreased to 31% in 2025 (2024: 39%), mainly due to change in product mix with more products with lower prices and margin in response to market dynamics and needs during the year.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the year, the Group launched a new gift set product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese-style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. In addition, based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of “tea and wine fusion,” has captured market attention with its unique craftsmanship. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Ningxia Winery won industry praise for their unique flavor and exquisite craftsmanship. In the second half of the year, the Group also introduced new products “Hi” tea-flavoured wine series in response to the market need, which are very suitable for ready-to-drink scenarios among young consumers.In addition to enriching the product matrix, the Group has been closely cooperating with distributors, pressing ahead with its marketing campaign, accelerating the innovation of consumption scenarios, and enhancing and strengthening the wine cultural experience. The Group held its national tour tasting and business events, new products launch ceremonies at various exhibitions and wine fairs, as well as promotion activities for the 20th anniversary of listing in Hong Kong, during which the Group actively promoted its latest product mix that covered all product lines.During the year, two joint venture companies approved by the Group were established in February 2025, for the manufacturing and sales of yellow wine and Chenpi wine and trading of sauce-flavour baijiu products nationwide in the PRC respectively. For the yellow wine project, installation and testing of production equipment of a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu is expected to be completed in the second half of 2026. Upon completion of the project, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry. The project expansion aims to effectively implement Dynasty’s strategic plan, further improving the industrial layout, expanding category tracks, tapping into industry potential, creating new performance growth points, and realising Dynasty Group’s transformation into a full category, full industry-chain enterprise. For the sauce-flavour baijiu segment, Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in the core-market in Tianjin and Shanghai and will be further strategically promoted to other regions in 2026. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales scale of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness.Regarding online sales, the e-commerce team of the Group comprehensively operates online stores itself on the traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based e-commerce platforms, including Rednote, Kuai and TikTok. The Group continues investing resources in a timely manner for improvement of the online sales channels and optimisation of online stores interface so as to capture the change of customer consumption behaviour in the PRC. The Group jointly develops exclusive products with leading e-commerce platforms, and promote AI livestreaming models in various channels to increase brand exposure and livestreaming sales, adopts big data analysis to accurately understand consumer demand, and injects strong momentum into the continued expansion of market scale. To establish an online brand matrix, the Group selected and authorised new online distributors during the year. The Group believes that the online platforms not only serve as business-to-customer trading platforms between the Group and the consumers, but also additional marketing and promotion channels for the brand, which can enhance the overall business potential of the Group.During the year, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series – Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world. Dynasty has won the Silver Medal in the Sparkling Wine/China category, the Silver Medal in the Dry Wine/China category, and the Bronze Medal in the Medium/China category for its Dynasty Tianyang Winery Jasmine Sparkling Wine, Dynasty Inherit Series – Dry Red Wine, and Dynasty Inherit Series – Semi Dry White Wine, respectively, at the 2025 Cathay Global Wine & Spirits Awards Asia (“GWSAA”) (formerly known as the Cathay Hong Kong International Wine & Spirit Competition (“HKIWSC”)). This marks the 15th consecutive year that Dynasty products have won awards at the event, demonstrating industry-wide recognition of Dynasty’s exceptional winemaking skill and quality. In addition, “Dynasty Pinyue VSOP brandy” also won the Gold Medal in the brandy category of 2025 China Fine Wine Challenge.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to 2026, the Group will continue to focus on market and consumer demand, reinvent consumption scenarios and promote product quality. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image as a representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to uphold quality, seize the development trend of low-alcohol and younger consumer markets, and proactively develop new marketing prospects through innovation in products categories and consumption scenarios.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China.For media enquiries:Strategic Financial Relations (China) LimitedMs. Anita Cheung Tel: 2864 4827Ms. Gianna Ye Tel: 2864 4837Ms. Hazel Ye Tel: 2864 4893Ms. Chloe Lyu Tel: 2864 4835Email: sprg-dynasty@sprg.com.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com